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A B S T R A C T
Background
Benign prostatic hyperplasia (BPH) is a common condition in ageing men that may cause lower urinary tract symptoms (LUTS).
Treatment aims are to relieve symptoms and prevent disease-related complications. Naftopidil is an alpha-blocker (AB) that has a high
affinity for the A1d receptor that may have advantages in treating LUTS in this setting. This is an update of a Cochrane Review first
published in 2009. Since that time, several large randomised controlled trials (RCTs) have been reported, making this update relevant.
Objectives
To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH.
Search methods
We performed a comprehensive search using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, LILAC, and
Web of Science), trials registries, other sources of grey literature, and conference proceedings with no restrictions on the language of
publication or publication status up to 31 May 2018
Selection criteria
We included all parallel RCTs. We also included cross-over design trials.
Data collection and analysis
Two review authors independently classified and abstracted data from the included studies. We performed statistical analyses using
a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. Primary
outcomes were urological symptom scores, quality of life (QoL) and treatment withdrawals for any reason; secondary outcomes were
treatment withdrawals due to adverse events, acute urinary retention, surgical intervention for BPH, and cardiovascular and sexual
adverse events. We considered outcomes measured up to 12 months after randomisation as short term, and later than 12 months as
long term. We rated the certainty of the evidence according to the GRADE approach.
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Main results
We included 22 RCTs with 2223 randomised participants across four comparisons for short-term follow-up. This abstract focuses on
only two of four comparisons for which we found data since two comparators (i.e. propiverine and Eviprostat (phytotherapy)) are
rarely used. One study comparing naftopidil to placebo did not report any relevant outcomes and was therefore excluded. There were
no trials that compared to combination therapy with naftopidil or any 5-alpha reductase inhibitors (5-ARIs) to combination therapy
with other ABs and any 5-ARIs.
All included studies were conducted in Asian countries. Study duration ranged from four to 12 weeks.Mean age was 67.8 years, prostate
volume was 35.4 mL, and International Prostate Symptom Score was 18.3. We were unable to perform any of the preplanned subgroup
analyses based on age and baseline symptom score.
Naftopidil versus tamsulosin
Based on 12 studies with 965 randomised participants, naftopidil may have resulted in little or no difference in urological symptom
score (mean difference (MD) 0.47, 95% confidence interval (CI) -0.09 to 1.04 measured on a scale from 0 to 35 with higher score
representing increased symptoms), QoL (MD 0.11, 95% CI -0.09 to 0.30; measured on a scale from 0 to 6 with higher scores
representing worse QoL), and treatment withdrawals for any reason (risk ratio (RR) 0.92, 95% CI 0.64 to 1.34; corresponding to 7
fewer per 1000 participants, 95% CI 32 fewer to 31 more). Naftopidil may have resulted in little to no difference in sexual adverse
events (RR 0.54, 95% CI 0.24 to 1.22); this would result in 26 fewer sexual adverse events per 1000 participants (95% CI 43 fewer
to 13 more). We rated the certainty of evidence as moderate for urological symptom score and low for the other outcomes.
Naftopidil versus silodosin
Based on five studies with 652 randomised participants, naftopidil may have resulted in little or no difference in the urological symptom
scores (MD 1.04, 95% CI -0.78 to 2.85), QoL (MD 0.21, 95% CI -0.23 to 0.66), and treatment withdrawals for any reason (RR
0.80, 95% CI 0.52 to 1.23; corresponding to 26 fewer per 1000 participants, 95% CI 62 fewer to 32 more). We rated the certainty of
evidence as low for all these outcomes. Naftopidil likely reduced sexual adverse events (RR 0.15, 95% CI 0.06 to 0.42; corresponding to
126 fewer sexual adverse events per 1000 participants, 95% CI 139 fewer to 86 fewer). We rated the certainty of evidence as moderate
for sexual adverse events.
Authors’ conclusions
Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin. Naftopidil
has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin.
P L A I N L A N G U A G E S U M M A R Y
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Review question
What are the effects of naftopidil in men with bothersome urinary symptoms due to an enlarged prostate?
Background
An enlarged prostate (called benign prostatic hyperplasia) can cause bothersome lower urinary tract symptoms such as having to urinate
often during the day or at night, having a weak urine stream, and having the feeling of not emptying the bladder completely. A common
reason for these complaints is an enlarged prostate, which is common in older men. Naftopidil is a medication that may help with
these symptoms and possibly cause fewer unwanted effects than other medications used for this problem. In this review, we compared
naftopidil to other medicines.
Study characteristics
We included 22 studies with 2223 men. The average age was 68.0 years. These men had mostly symptoms rated as moderate or severe.
Key results
Naftopidil may have had similar effects on urinary symptoms and QoL compared to tamsulosin and silodosin. In terms of unwanted
effects, naftopidil may have had similar unwanted sexual side effects compared to tamsulosin but have fewer compared to silodosin.
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Reliability of the evidence
The reliability of evidence for most symptoms was low. This means that the true effect may be substantially different from what this
review shows.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Naftopidil compared to tamsulosin (alpha-blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)
Participants: men with lower urinary tract symptoms suggest ing benign prostat ic hyperplasia
Setting: l ikely outpat ients
Intervention: naf topidil
Comparator: tamsulosin
Outcomes of participants
(studies)
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects* (95% CI)
Risk with tamsulosin Risk difference with nafto-
pidil
Urological symptom scores
assessed with: IPSS
Scale f rom: 0 (best: not at
all) to 35 (worst: almost al-
ways)
Follow-up: 4-12 weeks
965
(12 RCTs)
⊕⊕⊕©
Moderatea
- The mean urological symp-
tom scores ranged f rom 9.
2 to 10.7 (f rom 4 studies)
and mean change of urolog-
ical symptom scores ranged
f rom -9.8 to -3.3 (f rom 8 stud-
ies)
MD 0.47 higher
(0.09 lower to 1.04 higher)
Quality of life
assessed with: IPSS-Quality
of Life
Scale f rom: 0 (best: de-
lighted) to 6 (worst: terrible)
Follow-up: 4-12 weeks
878
(11 RCTs)
⊕⊕©©
Lowa,b
- The mean quality of lif e
ranged f rom 2.7 to 3.1 (f rom
3 studies) and mean change
of quality of lif e ranged f rom
-2.75 to -0.7 (f rom 8 studies)
MD 0.11 higher
(0.09 lower to 0.30 higher)
Treatment withdrawals for
any reason
Follow-up: 4-12 weeks
668
(8 RCTs)
⊕⊕©©
Lowa,c
RR 0.92
(0.64 to 1.34)
Study populat ion
90 per 1000 7 fewer per 1000
(32 fewer to 31 more)
4
N
a
fto
p
id
il
fo
r
th
e
tre
a
tm
e
n
t
o
f
lo
w
e
r
u
rin
a
r
y
tra
c
t
sy
m
p
to
m
s
c
o
m
p
a
tib
le
w
ith
b
e
n
ig
n
p
ro
sta
tic
h
y
p
e
rp
la
sia
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Cardiovascular adverse
events
Follow-up: 4-12 weeks
824
(9 RCTs)
⊕⊕©©
Lowa,c
RR 0.97
(0.52 to 1.80)
Study populat ion
58 per 1000 2 fewer per 1000
(28 fewer to 47 more)
Sexual adverse events
Follow-up: 4-12 weeks
397
(5 RCTs)
⊕⊕©©
Lowa,c
RR 0.54
(0.24 to 1.22)
Study populat ion
57 per 1000 26 fewer per 1000
(43 fewer to 13 more)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; IPSS: Internat ional Prostate Symptom Score; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by one level for study lim itat ions: unclear or high risk of bias in one or more domains.
bDowngraded by one level for inconsistency: moderate-to-substant ial heterogeneity.
cDowngraded by one level for imprecision: conf idence interval crossed assumed threshold of clinically important dif f erence.
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B A C K G R O U N D
Description of the condition
Benign prostatic hyperplasia (BPH) is a common condition
in elderly men and refers to the non-malignant proliferation
of smooth muscle, connective tissue, and glandular epithelium
within the prostate, which may result in prostatic urethra obstruc-
tion (Roehrborn 2008). The exact aetiology of BPH is currently
unknown. Several suggestive risk factors are ageing, familial his-
tory, changes in hormonal levels, elevated markers of inflamma-
tion, and metabolic syndrome (Russo 2015). Cellular prolifera-
tions in the periurethral and transition zones lead to the formation
of nodular adenomas, potentially distorting the bladder neck and
prostatic urethra. Such occurrence of anatomical changes and pro-
static obstruction result in lower urinary tract symptoms (LUTS).
There are two categories of LUTS; voiding symptoms (which in-
clude hesitancy, weak stream, urinary retention, postmicturition
dribble, straining, and incomplete emptying) and storage symp-
toms (such as frequency, urgency, and nocturia) (McVary 2011).
Generally, greater severity of LUTS relates to more detrimental
quality of life (QoL) and a greater desire for treatment (Agarwal
2014). Patient self-report using a validated urinary symptom scale,
such as International Prostate Symptom Score (IPSS), is used to
evaluate symptom severity and QoL; this is an integral part of epi-
demiological and treatment studies (Barry 1995). Increasing IPSS
symptom severity (LUTS severity) is also associated with patient
perception of bladder condition, which is regarded as men’s overall
distress and increased healthcare seeking (Chapple 2017). In this
Cochrane Review, we used the term BPH as prostatic enlargement
with LUTS through which to define the disease condition and
potential need for intervention.
Many of the complications of progressive BPH are rare, even
though untreated; however, bladder stones, bladder decompensa-
tion, urinary tract infections, haematuria, and azotaemia can oc-
cur, requiring medical or surgical intervention. BPH has also been
relatedwith othermedical conditions, reducedQoL, and increased
annual healthcare costs (Kaplan 2015; Kozminski 2015; Martin
2014).
Diagnosis
The diagnosis of BPH is based on followed clinical features; a
prostate enlargement, bothersome LUTS, and no other identified
causes for the urinary problems. The initial evaluation of BPH
includes medical history, symptom score questionnaires (IPSS),
physical examination including a digital rectal examination, uri-
nalysis, prostate-specific antigen (PSA) blood test, and frequency
volume chart (EAU 2017; McVary 2011). The IPSS question-
naire is composed of three domains related to storage symptoms
(frequency, urgency, and nocturia); four domains related to void-
ing symptoms (hesitancy, weak stream, intermittence, and incom-
plete emptying); and one QoL domain (AUA Practice Guidelines
Committee 2003; Barry 1992). Seven symptom domains use a 6-
point scale ranging from 0 (none) to 5 (five or more) (Barry 1992).
TheQoL domain is assigned a score from1 to 6 (ordinal and range
from 0 to 6: 0 = delighted, 1 = pleased, 2 = mostly satisfied, 3 =
mixed, 4 = mostly dissatisfied, 5 = unhappy, 6 = terrible) (AUA
Practice Guidelines Committee 2003; Barry 1992). Another vali-
dated symptom score questionnaire, BPH Impact Index (BII), was
developed to assess the effect of LUTS/BPH on men’s health. The
BII questionnaire is composed of four items: physical discomfort
(0 = none, 1 = only a little, 2 = some, 3 = a lot); worry item (0
= none, 1 = only a little, 2 = some, 3 = a lot); bother item (0
= not at all bothersome, 1 = bothers me a little, 2 = bothers me
some, 3 = bothers me a lot); the interference with usual activities
item (0 = none of the time, 1 = a little of the time, 2 = some of
the time, 3 = most of the time, 4 = all of the time) (Barry 1995).
Symptom score questionnaires should be delivered to objectively
identify and quantify LUTS. These are also sensitive to symptom
changes and treatment monitoring (EAU 2017; McVary 2011). A
digital rectal examination is an important examination and may
help to determine the coexistence of prostate cancer. Urinalysis is
useful for differential diagnosis to urinary tract infection. Together
with a digital rectal examination, a PSA test increases the detection
rate of prostate cancer, but would be performed if life expectancy
is greater than 10 years and if a diagnosis of prostate cancer would
modify the management approach (EAU 2017; McVary 2011).
Measurement of urinary flow rates and residual urine are help-
ful in diagnostic evaluation and treatment response (EAU 2017;
McVary 2011). A decreased urinary flow rate and large residual
urine are risk factors of symptom aggravation (Crawford 2006).
Other tests include radiological imaging, pressure flow study, and
urethrocystoscopy are not recommended as a routine diagnostic
procedure except in selective conditions which affect treatment
decisions (McVary 2011).
Treatment
The role of treatment for any disease process depends on the mag-
nitude of the clinical effect and the incidence and severity of treat-
ment-relatedmorbidity. In addition, the degree of bother resulting
fromBPHis themain factor for receiving a treatment. A significant
proportion of men with LUTS will not choose medical or surgi-
cal intervention because the symptoms are not bothersome. These
men are suitable for watchful waiting (Netto 1999) and lifestyle
modification (Yap 2009). Men who complain of moderate-to-
severe bother with symptoms are likely to benefit from medical
(alpha-blockers (ABs), 5-alpha reductase inhibitors (5-ARIs), and
combination therapy) or surgical treatment (EAU 2017; McVary
2011). ABs reduce smooth muscle tone in the prostate and blad-
der neck with/without 5-ARIs, which reduces prostate volume
by inducing epithelial atrophy. They are an established treatment
in LUTS/BPH and have been widely used as first-line therapy
since the late 1990s (McConnell 2003; Milani 2005; Yoo 2012).
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In particular, ABs that can decrease smooth muscle tone in the
prostate and bladder neck have been considered as fundamen-
tal pharmacotherapy for men with BPH (Cornu 2010; Milani
2005; Yoo 2012). Prior systematic reviews have shown that ABs
can typically reduce IPSS by 20% to 50% and increase Qmax by
15% to 45% (MacDonald 2005; Wilt 2006). ABs are the most
commonly prescribed category of drug for LUTS/BPH, account-
ing for about 70% of all medications prescribed in 2008 (Cornu
2010). Adverse effects of ABs include postural hypotension, dizzi-
ness, headache, asthenia, syncope, peripheral oedema, and ret-
rograde ejaculation, which cause approximately 4% to 10% of
men to withdraw from AB treatment (Djavan 1999; Gacci 2014;
MacDonald 2005; Schulman 2003; Wilt 2006). Other medical
therapies, such as anticholinergics and desmopressin, have been
used with ABs, depending on the main symptoms (Brasure 2016;
Dahm 2017; EAU 2017). Also, a phosphodiesterase type 5 in-
hibitor, tadalafil (5 mg once daily), has been licensed for the treat-
ment of male LUTS, and various plant extracts (e.g., Cucurbita
pepo; pumpkin seeds, Hypoxis rooperi; South African star grass,
Pygeum africanum; bark of the African plum tree, Secale cereale;
rye pollen, Serenoa repens; saw palmetto and Urtica dioica; roots
of the stingingnettle) have beenproposed for the treatment ofmale
LUTS (EAU 2017; Keehn 2016; Oelke 2012). Surgical treatment
was considered in cases of symptoms refractory to medical treat-
ment or traditional absolute indications (e.g. acute urinary reten-
tion (AUR), recurrent urinary tract infection, bladder stones or di-
verticula, haematuria, or renal insufficiency) (EAU 2017; McVary
2011).
Description of the intervention
Naftopidil is selective for the A1d adrenergic receptor with a three-
to 17-fold higher affinity than for the A1a and A1b adrenergic re-
ceptor subtypes based on in vitro studies andwas approved in Japan
in 1998 (Takei 1999).Naftopidil should bemore effective for stor-
age symptoms measured by IPSS due to its selectivity for the blad-
der via the A1d receptor subtype. Initial randomised controlled
trials (RCTs) found no significant difference in IPSS and QoL
(QoL) comparedwith tamsulosin (Ikemoto 2003; Ju 2002). Along
with these studies, several RCTs also reported that naftopidil was
as effective as tamsulosin (Momose 2007; Nishino 2006). There
were no significant differences in the incidence of adverse events
between the naftopidil and tamsulosin groups (Ikemoto 2003; Ju
2002;Momose 2007;Nishino 2006; Singh 2013;Ukimura 2008).
How the intervention might work
The A1a adrenergic receptors are a class of G protein-coupled re-
ceptors that consist of three homologous subtypes, including A1a,
A1b, and A1d receptors. The A1a receptor subtype predominates
in the human prostate, bladder neck, and urethra (Lepor 2016;
Michel 2000; Schwinn 2008). A1b receptor subtypes are mainly
expressed in the peripheral vasculature and are important in the
regulation of blood pressure. The A1d receptor is expressed in
the detrusor muscle of the bladder and the sacral region of the
spinal cord (Lepor 2016; Michel 2000; Schwinn 2008). Nafto-
pidil, which shows greater selectivity for A1d over the A1a sub-
type, was reported to be more effective in improving storage symp-
toms than tamsulosin with greater selectivity for the A1a over the
A1d subtype (Nishino 2006; Perumal 2015; Ukimura 2008). In
addition, experimental studies have shown that A1d-ARs greatly
outnumber A1a-ARs in the bladder and are upregulated in blad-
der outlet obstruction (Hampel 2002). Therefore, naftopidil may
have a therapeutic effect for BPH improving obstruction symp-
toms and storage symptoms with similar vascular adverse effects,
such as dizziness, orthostatic hypotension, which were commonly
observed in other ABs.
Why it is important to do this review
Naftopidil is not available in Western countries because of non-
Asian randomised clinical trials and lack of placebo-controlled tri-
als. Therefore, the potential advantages or harms of naftopidil (se-
lective A1d-AR blockade) in the treatment of LUTS cannot be
assessed until a drug with appropriate subtype selectivity becomes
available for clinical evaluation (Andersson 2007). One previous
Cochrane Review for naftopidil for the treatment of LUTSs com-
patible with BPH based on RCTs demonstrated that IPSS and
QoL improvement were similar to low-dose tamsulosin (0.2 mg/
day) but more improved compared to phytotherapy (Eviprostat)
and adverse events due to naftopidil were few and usually mild
(Garimella 2009). After publication of the Garimella 2009 re-
view, Cochrane introducedmore rigorous methodology, which in-
cluded assessment of risk of bias and production of ’Summary of
findings’ tables (the GRADE approach). Furthermore, results of
several randomised trials for naftopidil have been reported since
the Garimella 2009 review. Therefore, the previous review must
be considered outdated. This is an update of the Cochrane Review
first published in 2009 (Garimella 2009).
O B J E C T I V E S
To evaluate the effects of naftopidil, for the treatment of LUTS
associated with BPH.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We included parallel, RCTs regardless of their publication status
or language of publication. We also included cross-over designs.
Types of participants
We included adult men (aged 40 years and over) with LUTS/
BPH. The age limitation was based on the observation that the
prevalence of BPH increases in middle-aged and older men (Barry
1997; Egan 2016), and is infrequent in younger men.
We excluded trials of men with a known neurogenic bladder due
to spinal cord injury, multiple sclerosis, or central nervous system
disease, and men who had been previously treated with surgery for
BPH. We included studies that their data were available separately
for analysis rather than using the whole population.
Types of interventions
We investigated the following comparisons of experimental inter-
vention versus comparator intervention. Concomitant interven-
tions were allowed but had to be the same in the experimental and
comparator groups to establish fair comparisons.
Experimental interventions
• Naftopidil.
• Naftopidil plus any 5-ARIs (if available).
In the past, naftopidil 25 mg/day was initially administered, in-
creasing to 50 mg/day to 75 mg/day over an interval of one to two
weeks if needed (Yokoyama 2006). Currently, naftopidil 50 mg/
day is the initial clinical recommended dosage (Masumori 2011).
One study reported that naftopidil 75 mg/day was also useful for
Korean men with BPH to improve total IPSS and OABSS (Kwon
2018). We included trials with doses of naftopidil at 25 mg/day,
50 mg/day, and 75 mg/day.
Comparator interventions
• Placebo.
• Other ABs.
• Other ABs plus any 5-ARIs (if available).
• Anticholinergics.
• Phytotherapy. (e.g. plant extracts)
Comparisons
• Naftopidil versus placebo.
• Naftopidil versus other ABs.
• Naftopidil plus any 5-ARIs (If available) versus other ABs
plus any 5-ARIs (if available).
• Naftopidil versus anticholinergics.
• Naftopidil versus phytotherapy.
Types of outcome measures
Primary outcomes
• Urological symptom scores.
• QoL.
• Treatment withdrawals for any reason.
Secondary outcomes
• Treatment withdrawals due to adverse events.
• AUR.
• Surgical intervention for LUTS/BPH.
• Cardiovascular adverse events.
• Sexual adverse events.
Method and timing of outcome measurement
• Urological symptom scores: final value or change from
baseline assessed with a validated scale (such as IPSS).
• QoL: final value or change from baseline assessed with a
validated scale (such as IPSS-Quality of Life or BII scores).
• Treatment withdrawals for any reason: defined as treatment
discontinuation for any cause at any time after participants were
randomised to intervention/comparator groups.
• Treatment withdrawals due to adverse events: defined as
treatment discontinuation due to adverse events at any time after
participants were randomised to intervention/comparator
groups.
• AUR: events requiring catheterisation.
• Surgical intervention for LUTS/BPH: events requiring
other surgical treatment modalities (e.g. transurethral resection
of the prostate (TURP)).
• Cardiovascular adverse events: such as dizziness, headache,
orthostatic hypotension, and syncope.
• Sexual adverse events: such as retrograde ejaculation,
anejaculation, and decreased libido.
We used clinically important differences for the outcomes when
available to judge the magnitude of the effect in the context of
rating the certainty of the evidence in the ”Summary of finding’
tables (Jaeschke 1989; Johnston 2013).When themean difference
(MD) or risk ratio (RR) was equal to or larger than the minimal
clinically important difference (MCID), we assumed that many
participantsmay have gained a clinicallymeaningful improvement
from treatment.
We considered MCID in the IPSS to be 3 point, BII score to
be 0.5 points, and IPSS-Quality of Life to be 0.5 points (Barry
1995; Brasure 2016; Rees 2015). We did not establish thresholds
for treatment withdrawals due to adverse events, AUR, surgical
intervention for LUTS/BPH, cardiovascular adverse events, and
sexual adverse events. We considered the clinically important dif-
ferences of all listed outcomes above as a RR increase of at least
25% (Guyatt 2011a). We considered outcomes measured up to
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and including 12 months after randomisation as short term, and
later than 12 months as long term.
• Up to 12 months (short term).
• More than 12 months (long term).
Main outcomes for ’Summary of findings’ tables
Wepresented ’Summary of findings’ tables reporting the following
outcomes listed according to the perceived priority to men with
LUTS/BPH.
• Urological symptom scores.
• QoL.
• Treatment withdrawals for any reason.
• Cardiovascular adverse events.
• Sexual adverse events.
Search methods for identification of studies
We performed a comprehensive search with no restrictions on the
language of publication or publication status.We updated searches
within three months prior to the anticipated publication of the
review.
Electronic searches
We initially searched the following sources from inception of each
database to 8October 2017. The date of last search of all databases
was 31 May 2018. See Appendix 1.
• Cochrane Library (via Wiley):
◦ Cochrane Database of Systematic Reviews;
◦ Cochrane Central Register of Controlled Trials
(CENTRAL);
◦ Database of Abstracts of Reviews of Effects;
◦ Health Technology Assessment Database.
• MEDLINE (PubMed).
• Embase (Ovid).
• Scopus.
• LILAC (bvsalud.org/en).
• Web of Science.
We also searched the following trials registers on 8 October 2017
and 31 May 2018.
• ClinicalTrials.gov ( www.clinicaltrials.gov).
• World Health Organization International Clinical Trials
Registry Platform search portal ( apps.who.int/trialsearch/).
• Grey Literature Report ( www.opengrey.eu).
Searching other resources
We searched the reference lists of retrieved included trials, re-
views, meta-analyses, and health technology assessment reports to
identify other potentially eligible trials or ancillary publications.
We contacted study authors of included trials to identify any fur-
ther studies that we might have missed. We contacted drug/device
manufacturers for ongoing or unpublished trials. We searched for
unpublished studies by handsearching the abstract proceedings of
the annual meetings of the American Urological Association, Eu-
ropean Association of Urology, and International Continence So-
ciety for 2015 to 2017 and then updated the search in 2018.
Data collection and analysis
Selection of studies
We used reference management software to identify and remove
potential duplicate records (EndNote). Two review authors (ECH,
JHJ) independently scanned the abstract, title, or both, of remain-
ing records retrieved to determine which studies should be as-
sessed further. Two review authors (ECH, JHJ) investigated all
potentially relevant records as full text; mapped records to studies;
and classified studies as included studies, excluded studies, studies
awaiting classification, or ongoing studies, in accordance with the
criteria for each provided in theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011a). We used Covidence for
title/abstract, and full-text screening. We resolved any discrepan-
cies through consensus or recourse to a third review author (PD).
If resolution of a disagreement was not possible, we designated the
study as ’awaiting classification’ and contacted study authors for
clarification. We documented reasons for exclusion of studies that
may have reasonably been expected to be included in the review
in the Characteristics of excluded studies table. We presented an
adapted PRISMA flow diagram showing the process of study se-
lection (Liberati 2009).
Data extraction and management
We developed a dedicated data abstraction form that we pilot
tested ahead of time. For studies that fulfilled the inclusion crite-
ria, two review authors (ECH, JHJ) independently abstracted the
following information, which we provided in the Characteristics
of included studies table.
• Study design.
• Study dates.
• Study settings and country.
• Participant inclusion and exclusion criteria (e.g. age,
baseline IPSS).
• Participant details, baseline demographics (e.g. age, ethnic
background, IPSS).
• Number of participants by study and by study arm.
• Details of relevant experimental and comparator
interventions such as frequency (e.g. once daily or twice daily)
and treatment duration (in weeks or months).
• Definitions of relevant outcomes and method (e.g. type of
instrument such as IPSS) and timing of outcome measurement
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(e.g. in weeks or months) as well as any relevant subgroups (e.g.
based on age).
• Study funding sources.
• Declarations of interest by primary investigators.
We extracted outcome data relevant to this Cochrane Review as
needed for calculation of summary statistics and measures of vari-
ance. For dichotomous outcomes, we obtained numbers of events
and totals for completion of a 2 × 2 table, as well as summary
statistics with corresponding measures of variance. For continu-
ous outcomes, we obtained means and standard deviations or data
necessary to calculate this information. We attempted to contact
authors of included and excluded studies to obtain key missing
data as needed.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents,
or multiple reports of a primary study, we maximised yield of
information by mapping all publications to unique studies and
collating all available data. We used the most complete data-set
aggregated across all known publications. In case of doubt, we
gave priority to the publication reporting the longest follow-up
associated with our primary or secondary outcomes.
Assessment of risk of bias in included studies
Two review authors (SG, JHJ) independently assessed the risk of
bias of each included study. We resolved disagreements by con-
sensus, or by consultation with a third review author (PD).
We assessed risk of bias using Cochrane’s ’Risk of bias’ assessment
tool for the following domains (Higgins 2011b).
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other sources of bias (e.g. run-in period, absence of
washout period in cross-over trial, baseline imbalance).
We judged risk of bias domains as ’low risk,’ ’high risk,’ or ’un-
clear risk’ and evaluated individual bias items as described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b). We presented a ’Risk of bias’ summary figure to illustrate
these findings. For selection bias (random sequence generation and
allocation concealment), we evaluated risk of bias at a trial level.
For performance bias (blinding of participants and personnel), we
considered that all outcomes were susceptible to performance bias
and assessed in one group. For detection bias (blinding of outcome
assessment), we grouped outcomes as susceptible to detection bias
(subjective) or not susceptible to detection bias (objective) out-
comes. We defined the following outcomes as susceptible to bias
(subjective outcomes).
• Urological symptom scores.
• QoL.
• Treatment withdrawals for any reason.
• Treatment withdrawals due to adverse events.
• Cardiovascular adverse events.
• Sexual adverse events.
We defined the following outcomes as not susceptible to bias (ob-
jective outcomes).
• AUR.
• Surgical intervention for LUTS/BPH.
We initially assessed attrition bias (incomplete outcome data) on a
per-outcome basis but created groups of outcomes based on similar
reporting characteristic.
For reporting bias (selective reporting), we evaluated risk of bias
on a trial level.
We further summarised the risk of bias across domains for each
outcome in each included study, as well as across studies and do-
mains for each outcome, in accordance with the approach for sum-
mary assessments of the risk of bias presented in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011b).
Measures of treatment effect
We expressed dichotomous data as RRs with 95% confidence in-
tervals (CIs).We expressed continuous data asMDs with 95%CIs
unless different studies used different measures to assess the same
outcome, in which case we expressed data as standardised MDs
with 95% CIs.
Unit of analysis issues
The unit of analysis was the individual participant. For cross-over
trials or trials withmore than two intervention groups, we planned
to incorporate these study designs in meta-analyses in accordance
with guidance provided in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011c).
Dealing with missing data
We obtained missing data from study authors and performed in-
tention-to-treat analyses if data were available; we otherwise per-
formed available-case analyses. We investigated attrition rates, for
example, dropouts, losses to follow-up, and withdrawals, and crit-
ically appraised issues of missing data. We did not impute missing
data.
Assessment of heterogeneity
We identified heterogeneity (inconsistency) through visual inspec-
tion of the forest plots to assess the amount of overlap of CIs,
and the I2 statistic, which quantifies inconsistency across studies
to assess the impact of heterogeneity in the meta-analysis (Higgins
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2002; Higgins 2003); we interpreted the I2 statistic as follows
(Deeks 2011):
• 0% to 40%: may not be important;
• 30% to 60%: may indicate moderate heterogeneity;
• 50% to 90%: may indicate substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
When we found heterogeneity, we attempted to determine pos-
sible reasons for it by examining individual study and subgroup
characteristics.
Assessment of reporting biases
We attempted to obtain study protocols to assess for selective out-
come reporting. If we included 10 or more studies contributing in
a meta-analysis, we used funnel plots to assess small-study effects
(Sterne 2011). Several explanations can be offered for the asym-
metry of a funnel plot, including true heterogeneity of effect with
respect to trial size, poor methodological design (and hence bias
of small trials), and publication bias. Therefore, we interpreted
results carefully.
Data synthesis
We summarised data using a random-effects model. We inter-
preted random-effects meta-analyses with due consideration of the
whole distribution of effects. In addition, we performed statisti-
cal analyses according to the statistical guidelines contained in the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2011). For dichotomous outcomes, we used the Mantel-Haenszel
method; for continuous outcomes, we used the inverse variance
method. We used Review Manager 5 to perform analyses (Review
Manager 2014).
Subgroup analysis and investigation of heterogeneity
We expected the following characteristics to possibly introduce
clinical heterogeneity, and planned to carry out subgroup analyses
with investigation of interactions.
• Severity of baseline symptoms based on IPSS (0 to 7 =
mildly symptomatic; 8 to 19 = moderately symptomatic; 20 to
35 = severely symptomatic).
• Participant age (less than 65 years versus 65 years and older).
These subgroup analyses were based on the following observations.
• Relationship between changes in IPSS and participant
global ratings of improvement is influenced by the baseline
scores (Barry 1995).
• Tolerability of other ABs (as the main comparator) may
differ by participant age (Kozminski 2015; Lepor 2007).
We planned to perform subgroup analyses limited to the primary
outcomes.
Sensitivity analysis
We planned to perform sensitivity analyses limited to the primary
outcomes to explore the influence of the following factors (when
applicable) on effect sizes.
• Restricting the analysis by taking into account risk of bias,
by excluding studies at ’high risk’ or ’unclear risk’ of bias.
’Summary of findings’ tables
We presented the certainty of the evidence for each outcome ac-
cording to the GRADE approach, which takes into account five
criteria related to internal validity (risk of bias, inconsistency, im-
precision, publication bias) and external validity (directness of re-
sults) (Guyatt 2008). For each comparison, two review authors
(ECH, JHJ) independently rated the certainty of the evidence
for each outcome as ’high,’ ’moderate,’ ’low,’ or ’very low’ using
GRADEpro GDT 2015. We resolved any discrepancies by con-
sensus, or, if needed, by arbitration by a third review author (PD).
For each comparison, we presented a summary of the evidence
for the main outcomes in the ’Summary of findings’ tables, which
provides key information about the best estimate of themagnitude
of the effect in relative terms and absolute differences for each rel-
evant comparison of alternative management strategies; numbers
of participants and studies addressing each important outcome;
and the rating of the overall confidence in effect estimates for each
outcome (Guyatt 2011b; Schünemann 2011).
R E S U L T S
Description of studies
Results of the search
We identified 537 records through electronic database searching,
five records in trials registers, and two records in reference lists of
reviews. We found no records in the grey literature repository or
through handsearching abstract proceedings of relevant meetings
from 2015 to 2017. After removal of duplicates, we screened the
titles and abstracts of 309 records, and excluded 267 obviously ir-
relevant records. We screened 42 full-text articles (34 studies), and
excluded 10 records (10 studies) that did not meet the inclusion
criteria or were not relevant to the review. Two studies are awaiting
classification. We included 22 studies (30 records) in the review.
The flow of literature through the assessment process is shown in
the PRISMA flowchart (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Details of included studies are presented in the Characteristics of
included studies table; Table 1; and Table 2.
Source of data
We included 21 published studies and one abstract proceeding
(Fujihara 2010). Search of the electronic databases identified 21
published studies. Seventeen studies were published in English,
three were published in Japanese (Hanyu 2010;Masuda 2012; Ub
2016), and two were published in Chinese (Ju 2002; Li 2007),
which were translated into English by two review authors (MI,
RP) or using Google translator. We attempted to contact all cor-
responding authors of included trials to obtain additional infor-
mation on study methodology and results, and received replies
from three (Kwon 2018; Yamaguchi 2013; Yokoyama 2011; see
Appendix 2).
Study design and settings
We included 17 parallel, RCTs (Fujihara 2010; Gotoh 2005;
Griwan 2014; Hanyu 2010; Ju 2002; Kwon 2018; Li 2007;
Masumori 2009; Matsukawa 2017; Perumal 2015; Shirakawa
2013; Singh 2013; Ukimura 2008; Yamaguchi 2013; Yamanishi
2004; Yokoyama 2009; Yokoyama 2011), and five cross-over trials
(Ikemoto 2003; Masuda 2012; Momose 2007; Nishino 2006; Ub
2016). Four of 22 studies were reported as ’double-blinded.’ One
study blinded participants and investigators (Griwan 2014). Three
study were reported to be ’double-blinded’ but it was unclear who
was blinded (Ju 2002; Nishino 2006; Singh 2013). Three stud-
ies were open-label trials (Li 2007; Matsukawa 2017; Shirakawa
2013). The remaining 10 trials had no information regarding
blinding. There was one trial with run-in periods (Yamanishi
2004).
All studies were probably conducted in an outpatient clinic setting.
Five studies explicitly stated that the trial was conducted in an out-
patient clinic setting (Matsukawa 2017; Momose 2007; Perumal
2015; Singh 2013; Yamanishi 2004). All included studieswere per-
formed inAsia (Korea, Japan, China, and India). Twelve trials were
multicentre (Fujihara 2010; Gotoh 2005; Hanyu 2010; Kwon
2018; Li 2007;Masuda 2012;Masumori 2009;Matsukawa 2017;
Ub 2016; Ukimura 2008; Yamaguchi 2013; Yokoyama 2009).
The studies were performed from 2002 to 2017.
Participants
We included 2223 randomised participants (naftopidil 1086, tam-
sulosin 723, silodosin 383, propiverine 18, Eviprostat 13), of
which 1612 completed the trials (naftopidil 793, tamsulosin 451,
silodosin 337, propiverine 18, Eviprostat 13). However, two stud-
ies that compared naftopidil to tamsulosin did not report the num-
ber of participants randomised to each group (Ub 2016; Ukimura
2008), and four studies did not report the number of participants
who completed the trial in each group (Fujihara 2010;Kwon 2018;
Li 2007; Perumal 2015). All studies included men aged over 40
years. The mean age was 67.8 years, prostate volume was 35.4 mL,
and IPSS was 18.3.
All studies included participants with LUTS. Three studies in-
cluded participants with IPSS more than 13 (Griwan 2014; Ju
2002; Li 2007). Four studies did not specify the inclusion crite-
ria for LUTS in detail (Fujihara 2010; Momose 2007; Nishino
2006; Perumal 2015). One study included participants who had
been taking tamsulosin for eight weeks; however, participants had
persistent overactive bladder symptoms (Kwon 2018). Ten studies
used a Qmax of 15 mL/s as an inclusion criterion (Gotoh 2005;
Griwan 2014; Ikemoto 2003; Ju 2002; Li 2007;Matsukawa 2017;
Shirakawa 2013; Singh 2013; Ukimura 2008; Yamanishi 2004).
Major exclusion criteria included LUTS from any cause other than
BPH, prior treatment with other BPH medical therapy, recent
AUR, raised PSA level suspicious of prostate cancer, history of
prostate cancer, or prior prostate-related surgery.
Interventions
All studies administered naftopidil as an oral dose of 25 mg to 75
mg once daily.
Comparators
Studies used four different comparators, namely tamsulosin, silo-
dosin, propiverine, and Eviprostat. All comparators were admin-
istrated orally. Tamsulosin was administered as an oral dose of 0.2
mg (Fujihara 2010; Gotoh 2005; Hanyu 2010; Ikemoto 2003;
Ju 2002; Kwon 2018; Li 2007; Masumori 2009; Momose 2007;
Nishino 2006; Ukimura 2008; Yokoyama 2011), or 0.4 mg once
daily (Griwan 2014; Perumal 2015; Singh 2013). One study used
tamsulosin 0.2 mg plus solifenacin 5 mg once daily as a com-
parator (Ub 2016). Silodosin was administered as an oral dose
of 4 mg to 8 mg once daily (Masuda 2012; Matsukawa 2017;
Shirakawa 2013; Yamaguchi 2013; Yokoyama 2011). Propiverine
was administered as an oral dose of 20 mg once daily (Yokoyama
2009). Eviprostat was administered as an oral dose of six tablets
once daily (Yamanishi 2004).
Nine studies had a duration of intervention of 12 weeks (Fujihara
2010; Gotoh 2005; Griwan 2014; Hanyu 2010; Masumori
2009;Matsukawa 2017; Singh 2013; Yamaguchi 2013; Yokoyama
2011). Six studies followed the participants for four weeks to eight
weeks (Ju 2002; Kwon 2018; Shirakawa 2013; Ukimura 2008;
13Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yamanishi 2004; Yokoyama 2009). Li 2007 reported 12-month
follow-up data. For cross-over trials, two trials reported four weeks’
follow-up (Momose 2007; Nishino 2006), one trial reported six
weeks’ follow-up (Masuda 2012), and two trials reported eight
weeks’ follow-up (Ikemoto 2003; Ub 2016), before the cross-over.
Comparisons
We included four comparisons in this review: 16 studies compared
naftopidil to tamsulosin (Fujihara 2010; Gotoh 2005; Griwan
2014;Hanyu 2010; Ikemoto 2003; Ju 2002; Kwon 2018; Li 2007;
Masumori 2009; Momose 2007; Nishino 2006; Perumal 2015;
Singh 2013;Ub2016;Ukimura 2008; Yokoyama 2011), five stud-
ies compared naftopidil to silodosin (Masuda 2012; Matsukawa
2017; Shirakawa 2013; Yamaguchi 2013; Yokoyama 2011), one
study compared naftopidil to propiverine (Yamanishi 2004), and
one study compared naftopidil to Eviprostat (Yamanishi 2004).
All studies used naftopidil or other ABs as monotherapy. None of
the trials compared combination therapy with naftopidil or any
5-ARIs to combination therapy with other ABs and any 5-ARIs.
Outcomes
We identified all primary outcomes in each of the included studies
for four comparisons. Several studies did not report our prede-
fined secondary outcomes. However, we were able to obtain addi-
tional information by contact with the study authors (Kwon 2018;
Yamaguchi 2013; Yokoyama 2011). Given the nature of cross-
over design studies, we assumed they were not applicable to the
outcomes of AUR and surgical intervention for LUTS/BPH for
the analysis. Other secondary outcomes were reported in at least
one of the included studies.
Funding sources and conflicts of interest
One study reported no funding source (Fujihara 2010), and three
reported the funding source (one supported by National program
(Li 2007), and two supported by a university (Nishino 2006;
Perumal 2015)). The remaining trials did not mention a funding
source. Seven studies reported no conflicts of interest (Gotoh
2005; Griwan 2014; Nishino 2006; Perumal 2015; Shirakawa
2013; Yamaguchi 2013; Yokoyama 2009). The remaining studies
did not mention conflicts of interest.
Excluded studies
We excluded 10 studies (10 records) out of 34 studies (41 records)
after evaluation of the full-text publications. One study was a com-
mentary (Carson 2017) andonewas a review (Ikemoto 2010). Five
studies had an ineligible comparator (Hiroshi 2011; Maruyama
2006; Sakai 2011; Tsuritani 2010; Yokoyama 2006). One study
had an ineligible study design (Hayashi 2002). Two studies had
an ineligible study outcome (Yamaguchi 1992; Yamaguchi 1997).
However, since there was the possibility that outcomes of inter-
est were measured but not reported, we contacted the first author
of the studies and received replies (see Appendix 2). Details of
excluded studies are presented in the Characteristics of excluded
studies table.
Studies awaiting classification
We found two studies awaiting classification, which did not pro-
vide usable outcome data (NCT01203371; NCT01922375; see
Characteristics of studies awaiting classification table).
Ongoing trials
We found no ongoing studies.
Risk of bias in included studies
See the ’Risk of bias’ table within the Characteristics of included
studies table for further details; Figure 2; and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
• We rated 11 studies at low risk of bias (Griwan 2014;
Hanyu 2010; Ikemoto 2003; Kwon 2018; Masumori 2009;
Matsukawa 2017; Shirakawa 2013; Singh 2013; Yamaguchi
2013; Yamanishi 2004; Yokoyama 2011), and three studies at
high risk of bias (Masuda 2012; Perumal 2015; Ukimura 2008).
The remaining studies were at unclear risk of bias.
Allocation concealment
• We rated one study at low risk of bias (Yokoyama 2011);
the remaining studies were at unclear risk of bias.
Blinding
Blinding of participants and personnel
• We rated one study at low risk of bias (Griwan 2014). We
judged six studies at high risk of bias (Li 2007; Matsukawa 2017;
Shirakawa 2013; Ub 2016; Yamanishi 2004; Yokoyama 2011),
and the remaining studies at unclear risk of bias.
Blinding of outcome assessment
• Susceptible (subjective: urological symptom scores, QoL,
treatment withdrawal for any reason, treatment withdrawal due
to adverse events, cardiovascular adverse events, and sexual
adverse events) outcomes: we rated three studies at low risk of
bias for susceptible (subjective) outcomes (Griwan 2014;
Matsukawa 2017; Singh 2013). We judged two studies at high
risk of bias (Shirakawa 2013; Ub 2016), and the remaining
studies at unclear risk of bias.
• Not susceptible (objective: AUR and surgical intervention
for LUTS/BPH) outcomes: we rated all studies at low risk of bias
for objective outcomes because objective outcomes are unlikely
to be affected by lack of blinding.
Incomplete outcome data
• Urological symptom scores and QoL: we rated six studies at
low risk of bias (Griwan 2014; Ju 2002; Nishino 2006;
Shirakawa 2013; Singh 2013; Yamanishi 2004). We judged eight
studies at high risk of bias (Gotoh 2005; Hanyu 2010; Ikemoto
2003; Masuda 2012; Masumori 2009; Ub 2016; Ukimura 2008;
Yamaguchi 2013), and the remaining studies at unclear risk of
bias.
• Treatment withdrawal for any reason: we rated 17 studies at
low risk of bias (Gotoh 2005; Griwan 2014; Hanyu 2010;
Ikemoto 2003; Ju 2002; Li 2007; Masuda 2012; Masumori
2009; Matsukawa 2017; Momose 2007; Nishino 2006;
Shirakawa 2013; Singh 2013; Yamaguchi 2013; Yamanishi 2004;
Yokoyama 2009; Yokoyama 2011), and the remaining at unclear
risk of bias.
• Treatment withdrawal due to adverse events: we rated 15
studies at low risk of bias (Gotoh 2005; Griwan 2014; Hanyu
2010; Ikemoto 2003; Ju 2002; Masuda 2012; Masumori 2009;
Matsukawa 2017; Momose 2007; Nishino 2006, Shirakawa
2013; Singh 2013; Yamaguchi 2013; Yamanishi 2004; Yokoyama
2009), and the remaining studies at unclear risk of bias.
• AUR and surgical intervention for LUTS/BPH: we rated
two studies at low risk of bias (Singh 2013; Yamaguchi 2013),
and the remaining studies at unclear risk of bias.
• Cardiovascular adverse events: we rated 10 studies at low
risk of bias (Gotoh 2005; Griwan 2014; Ikemoto 2003; Ju 2002;
Masumori 2009; Matsukawa 2017; Nishino 2006; Shirakawa
2013; Singh 2013; Yamaguchi 2013), and one study at high risk
of bias (Ub 2016). The remaining studies were at unclear risk of
bias.
• Sexual adverse events: we rated seven studies at low risk of
bias (Griwan 2014; Masumori 2009; Nishino 2006; Shirakawa
2013; Singh 2013; Yamaguchi 2013; Yokoyama 2011), and one
study at high risk bias (Ub 2016). The remaining studies were at
unclear risk of bias.
Selective reporting
• We rated one study at low risk of bias (Shirakawa 2013).
We judged two studies) at high risk of bias (Ju 2002; Li 2007),
and the remaining studies at unclear risk of bias.
Other potential sources of bias
• We rated 13 studies at low risk of bias (Gotoh 2005;
Griwan 2014; Hanyu 2010; Ju 2002; Li 2007; Matsukawa 2017;
Nishino 2006; Perumal 2015; Shirakawa 2013; Singh 2013;
Ukimura 2008; Yamaguchi 2013; Yokoyama 2009). We judged
four studies at high risk of bias due to clinically important
imbalances in baseline characteristics and for selectively enrolling
participants who had a poor response to other ABs (Kwon 2018;
Masuda 2012; Masumori 2009; Yokoyama 2011). The
remaining studies were at unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Naftopidil
compared to tamsulosin (alpha-blocker) for the treatment of
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lower urinary tract symptoms compatible with benign prostatic
hyperplasia (short term); Summary of findings 2 Naftopidil
compared to silodosin (alpha-blocker) for the treatment of
lower urinary tract symptoms compatible with benign prostatic
hyperplasia (short term); Summary of findings 3 Naftopidil
compared to propiverine (anticholinergic) for the treatment of
lower urinary tract symptoms compatible with benign prostatic
hyperplasia (short term); Summary of findings 4 Naftopidil
compared to Eviprostat (phytotherapy) for the treatment of
lower urinary tract symptoms compatible with benign prostatic
hyperplasia (short term)
1. Naftopidil versus tamsulosin
See: Summary of findings for the main comparison.
1.1. Urological symptom scores
We included 12 RCTs with 965 participants in the analysis
(naftopidil 482, tamsulosin 483) (Fujihara 2010; Gotoh 2005;
Griwan 2014; Hanyu 2010; Ikemoto 2003; Ju 2002; Kwon
2018; Masumori 2009; Momose 2007; Nishino 2006; Ukimura
2008; Yokoyama 2011). We used the final value in four studies
(Ikemoto 2003; Nishino 2006; Ukimura 2008; Yokoyama 2011),
and change from baseline in the remaining studies. Naftopidil
may have resulted in little to no difference in urological symptom
scores (MD 0.47, 95% CI -0.09 to 1.04; I2 = 17%). We rated the
certainty of the evidence as moderate, downgrading for study lim-
itations (Analysis 1.1). The funnel plot showed symmetry thereby
suggesting no publication bias (Figure 4).
Figure 4. Funnel plot of comparison: 1 Naftopidil versus tamsulosin, outcome: 1.1 International Prostate
Symptom Score.
1.2. Quality of life
We included 11 RCTs with 878 participants in the analysis (nafto-
pidil 434, tamsulosin 444) (Fujihara 2010; Gotoh 2005; Griwan
2014; Hanyu 2010; Ikemoto 2003; Kwon 2018;Masumori 2009;
Momose 2007; Nishino 2006; Ukimura 2008; Yokoyama 2011).
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Weused final value in three studies (Ikemoto 2003; Nishino 2006;
Ukimura 2008), and change from baseline in the remaining stud-
ies. Naftopidil may have resulted in little to no difference in QoL
(MD 0.11, 95% CI -0.09 to 0.30; I2 = 52%). We rated the cer-
tainty of the evidence as low, downgrading for study limitations,
inconsistency, and concerns about publication bias due to funnel
plot asymmetry (Analysis 1.2; Figure 5).
Figure 5. Funnel plot of comparison: 1 Naftopidil versus tamsulosin, outcome: 1.2 International Prostate
Symptom Score-Quality of Life.
1.3. Treatment withdrawal for any reason
We included eight RCTs with 668 participants in the analysis
(naftopidil 335, tamsulosin 333) (Griwan 2014; Hanyu 2010;
Ju 2002; Masumori 2009; Momose 2007; Nishino 2006; Singh
2013; Yokoyama 2011).Naftopidilmay have resulted in little to no
difference in treatment withdrawal for any reason (RR 0.92, 95%
CI 0.64 to 1.34; I2 = 0%).We rated the certainty of the evidence as
low, downgrading for study limitations and imprecision (Analysis
1.3).
1.4. Treatment withdrawals due to adverse events
We included nine RCTs with 735 participants in the analysis
(naftopidil 366, tamsulosin 369) (Griwan 2014; Hanyu 2010;
Ikemoto 2003; Ju 2002;Masumori 2009;Momose 2007; Nishino
2006; Singh 2013; Yokoyama 2011). For the cross-over trials, we
used only the number of participants who had been initially ran-
domised due to lack of information about the number of partici-
pants in the analysis (Ikemoto 2003; Momose 2007). Naftopidil
may have resulted in little to no difference in treatmentwithdrawal
due to adverse events (RR 1.82, 95% CI 0.72 to 4.61; I2 = 0%).
We rated the certainty of the evidence as low downgrading for
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study limitations and imprecision (Analysis 1.4).
1.5. Acute urinary retention
We included three RCTs with 272 participants in the analy-
sis (naftopidil 142, tamsulosin 130) (Hanyu 2010; Singh 2013;
Yokoyama 2011). We found no events for AUR in two studies
(Hanyu 2010; Yokoyama 2011). Naftopidil likely resulted in little
to no difference in AUR (RR 0.82, 95% CI 0.23 to 2.86). We
rated the certainty of the evidence as moderate, downgrading for
imprecision (few events, few participants, and wide CIs) (Analysis
1.5).
1.6. Surgical intervention for lower urinary tract
symptoms/benign prostatic hyperplasia
We included two RCTs with 171 participants in the analysis
(naftopidil 92, tamsulosin 79) (Hanyu 2010; Yokoyama 2011).
There were no events for surgical intervention for LUTS/BPH in
either group (Analysis 1.6).
1.7. Cardiovascular adverse events
We included nine RCTs with 824 participants in the analysis
(naftopidil 413, tamsulosin 411) (Gotoh 2005; Griwan 2014;
Hanyu 2010; Ju 2002; Masumori 2009; Momose 2007; Nishino
2006; Singh 2013; Yokoyama 2011). For cross-over trials, we took
all measurements from naftopidil periods and all measurements
from tamsulosin periods (Momose 2007). Naftopidil may have
resulted in little to no difference in cardiovascular adverse events
(RR 0.97, 95% CI 0.52 to 1.80; I2 = 14%). We rated the certainty
of the evidence as low, downgrading for study limitations and im-
precision (Analysis 1.7).
1.8. Sexual adverse events
We included five RCTs with 397 participants in the analysis
(naftopidil 204, tamsulosin 193) (Hanyu 2010; Masumori 2009;
Nishino 2006; Singh 2013; Yokoyama 2011).Naftopidil may have
resulted in little to no difference in sexual adverse events (RR 0.54,
95% CI 0.24 to 1.22; I2 = 0%). We rated the certainty of the evi-
dence as low, downgrading for study limitations and imprecision
(Analysis 1.8).
Subgroup analysis
We were unable to perform any of the predefined subgroup anal-
yses.
Sensitivity analysis
We rated all of the included studies at high or unclear risk of bias
and were unable to perform a sensitivity analysis.
2. Naftopidil versus silodosin
See: Summary of findings 2.
2.1. Urological symptom scores
We included five RCTs with 652 participants in the analysis
(naftopidil 327, silodosin 325) (Masuda 2012; Matsukawa 2017;
Shirakawa 2013; Yamaguchi 2013; Yokoyama 2011). We used
change from baseline. Naftopidil may have resulted in little to no
difference in urological symptom scores (MD 1.04, 95% CI -0.78
to 2.85; I2 = 84%). We rated the certainty of the evidence as low,
downgrading for study limitations and inconsistency (Analysis
2.1).
2.2. Quality of life
We included five RCTs with 652 participants in the analysis
(naftopidil 327, silodosin 325) (Masuda 2012; Matsukawa 2017;
Shirakawa 2013; Yamaguchi 2013; Yokoyama 2011). We used
change from baseline. Naftopidil may have resulted in little to no
difference in QoL (MD 0.21, 95% CI -0.23 to 0.66; I2 = 92%).
We rated the certainty of the evidence as low, downgrading for
study limitations and inconsistency (Analysis 2.2).
2.3. Treatment withdrawals for any reason
We included four RCTs with 659 participants in the analy-
sis (naftopidil 325, silodosin 334) (Matsukawa 2017; Shirakawa
2013; Yamaguchi 2013; Yokoyama 2011). Naftopidil may have
resulted in little to no difference in treatment withdrawal for any
reason (RR 0.80, 95% CI 0.52 to 1.23; I2 = 0%). We rated the
certainty of the evidence as low, downgrading for study limitations
and imprecision (Analysis 2.3).
2.4. Treatment withdrawals due to adverse events
We included five RCTs with 738 participants in the analysis
(naftopidil 366, silodosin 372) (Masuda 2012; Matsukawa 2017;
Shirakawa 2013; Yamaguchi 2013; Yokoyama 2011). For the
cross-over trial, we used only the number of participants who had
been initially randomised due to lack of information about the
number of participants in the analysis (Masuda 2012). Naftopidil
may have resulted in little to no difference in treatmentwithdrawal
due to adverse events (RR 0.72, 95% CI 0.35 to 1.51; I2 = 0%).
We rated the certainty of the evidence as low downgrading for
study limitations and imprecision (Analysis 2.4).
2.5. Acute urinary retention
We included two RCTs with 180 participants in the analysis
(naftopidil 86, silodosin 94) (Yamaguchi 2013; Yokoyama 2011).
There were no events for AUR in either group (Analysis 2.5).
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2.6. Surgical intervention for lower urinary tract
symptoms/benign prostatic hyperplasia
We included two RCTs with 180 participants in the analysis
(naftopidil 86, silodosin 94) (Yamaguchi 2013; Yokoyama 2011).
There were no events for surgical intervention for LUTS/BPH in
either group (Analysis 2.6).
2.7. Cardiovascular adverse events
We included five RCTs with 808 participants in the analysis
(naftopidil 397, silodosin 411) (Masuda 2012; Matsukawa 2017;
Shirakawa 2013; Yamaguchi 2013; Yokoyama 2011). For the
cross-over trial, we took all measurements from naftopidil peri-
ods and all measurements from silodosin periods (Masuda 2012).
Naftopidil may have resulted in little to no difference in cardiovas-
cular adverse events (RR 0.98, 95% CI 0.39 to 2.44; I2 = 0%). We
rated the certainty of the evidence as low downgrading for study
limitations and imprecision (Analysis 2.7).
2.8. Sexual adverse events
We included four RCTs with 348 participants in the analysis
(naftopidil 172, silodosin 176) (Masuda 2012; Shirakawa 2013;
Yamaguchi 2013; Yokoyama 2011). For the cross-over trial, we
took all measurements from naftopidil periods and all measure-
ments from silodosin periods (Masuda 2012). Naftopidil likely
decreased sexual adverse events (RR 0.15, 95% CI 0.06 to 0.42;
I2 = 0%). Naftopidil would result in 126 fewer sexual adverse
events per 1000 men (95% CI 139 fewer to 86 fewer). We rated
the certainty of the evidence as moderate, downgrading for study
limitations (Analysis 2.8).
Subgroup analysis
We were unable to perform any of the predefined subgroup anal-
yses.
Sensitivity analysis
We rated all of the included studies as high or unclear risk of bias
and were unable to perform a sensitivity analysis.
3. Naftopidil versus propiverine
See: Summary of findings 3.
3.1. Urological symptom scores
We included one RCT with 37 participants in the analysis (nafto-
pidil 19, propiverine 18) (Yokoyama 2009). Naftopidil may have
resulted in little to no difference in urological symptom scores
(MD -2.80, 95% CI -6.99 to 1.39). We rated the certainty of the
evidence as low, downgrading for study limitations and impreci-
sion (Analysis 3.1).
3.2. Quality of life
We included one RCT with 37 participants in the analysis (nafto-
pidil 19, propiverine 18) (Yokoyama 2009). Naftopidil may have
resulted in little to no difference in QoL (MD 0.10, 95% CI -0.56
to 0.76). We rated the certainty of the evidence as low, downgrad-
ing for study limitations and imprecision (Analysis 3.2).
3.3. Treatment withdrawals for any reason; treatment
withdrawals due to adverse events; acute urinary retention;
surgical intervention for lower urinary tract
symptoms/benign prostatic hyperplasia; cardiovascular
adverse events; sexual adverse events
We found no studies that reported these outcomes.
Subgroup analysis
We were unable to perform any of the predefined subgroup anal-
yses.
Sensitivity analysis
We were unable to perform a sensitivity analysis because there was
only one study.
4. Naftopidil versus Eviprostat
See: Summary of findings 4.
4.1. Urological symptom scores
We included one RCT with 49 participants in the analysis (nafto-
pidil 36, Eviprostat 13) (Yamanishi 2004). Naftopidil likely re-
duced urological symptom scores (MD -6.30, 95% CI -9.46 to -
3.14). We rated the certainty of the evidence as moderate, down-
grading for study limitations (Analysis 4.1).
4.2. Quality of life
We included one RCT with 49 participants in the analysis (nafto-
pidil 36, Eviprostat 13) (Yamanishi 2004). Naftopidil likely in-
creased QoL (MD -1.50, 95% CI -2.36 to -0.64). We rated the
certainty of the evidence as moderate, downgrading for study lim-
itations (Analysis 4.2).
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4.3. Treatment withdrawals for any reason
We included one RCT with 49 participants in the analysis (nafto-
pidil 36, Eviprostat 13) (Yamanishi 2004). There were no events
for treatment withdrawal for any reason (Analysis 4.3).
4.4. Treatment withdrawals due to adverse events
We included one RCT with 49 participants in the analysis (nafto-
pidil 36, Eviprostat 13) (Yamanishi 2004). There were no events
for treatment withdrawal due to adverse events (Analysis 4.4).
4.5. Acute urinary retention; surgical intervention for lower
urinary tract symptoms/benign prostatic hyperplasia;
cardiovascular adverse events; sexual adverse events
We found no studies that reported these outcomes.
Subgroup analysis
We were unable to perform any of the predefined subgroup anal-
yses.
Sensitivity analysis
We were unable to perform a sensitivity analysis because there was
only one study.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Naftopidil compared to silodosin (alpha-blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)
Participants: men with lower urinary tract symptoms suggest ing benign prostat ic hyperplasia
Setting: l ikely outpat ients
Intervention: naf topidil
Comparator: silodosin
Outcomes of participants
(studies)
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects* (95% CI)
Risk with silodosin Risk difference with nafto-
pidil
Urological symptom scores
Assessed with: IPSS
Scale f rom: 0 (best: not at
all) to 35 (worst: almost al-
ways)
Follow-up: 6-12 weeks
652
(5 RCTs)
⊕⊕©©
Lowa,b
- The mean change of urolog-
ical symptom scores ranged
f rom -8.6 to -4.9
MD 1.04 higher
(0.78 lower to 2.85 higher)
Quality of life
Assessed with: IPSS-QoL
Scale f rom: 0 (best: de-
lighted) to 6 (worst: terrible)
Follow-up: 6-12 weeks
652
(5 RCTs)
⊕⊕©©
Lowa,b
- The mean change of quality
of lif e ranged f rom -2.0 to -0.
98
MD 0.21 higher
(0.23 lower to 0.66 higher)
Treatment withdrawals for
any reason
Follow-up: 8-12 weeks
659
(4 RCTs)
⊕⊕©©
Lowa,c
RR 0.80
(0.52 to 1.23)
Study populat ion
129 per 1000 26 fewer per 1000
(62 fewer to 30 more)
Cardiovascular adverse
events
Follow-up: 6-12 weeks
808
(5 RCTs)
⊕⊕©©
Lowa,c
RR 0.98
(0.39 to 2.44)
Study populat ion
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24 per 1000 0 fewer per 1000
(15 fewer to 35 more)
Sexual adverse events
Follow-up: 6-12 weeks
348
(4 RCTs)
⊕⊕⊕©
Moderatea
RR 0.15
(0.06 to 0.42)
Study populat ion
148 per 1000 126 fewer per 1000
(139 fewer to 86 fewer)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; IPSS: Internat ional Prostate Symptom Score;MD: mean dif ference; IPSS-QoL: Internat ional Prostate Symptom Score - Quality of Life; RCT: randomised
controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by one level for study lim itat ions: unclear or high risk of bias in one or more domains.
bDowngraded by one level for inconsistency: substant ial heterogeneity.
cDowngraded by one level in imprecision: conf idence interval crossed assumed threshold of clinically important dif f erence.
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Naftopidil compared to propiverine (anticholinergic) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)
Participants: men with lower urinary tract symptoms suggest ing benign prostat ic hyperplasia
Setting: l ikely outpat ients
Intervention: naf topidil
Comparator: propiverine
Outcomes of participants
(studies)
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects* (95% CI)
Risk with propiverine Risk difference with nafto-
pidil
Urological symptom scores
assessed with: IPSS
Scale f rom: 0 (best: not at
all) to 35 (worst: almost al-
ways)
Follow-up: mean 4 weeks
37
(1 RCT)
⊕⊕©©
Lowa,b
- The mean change of urologi-
cal symptom scores was -2.1
MD 2.8 lower
(6.99 lower to 1.39 higher)
Quality of life
assessed with: IPSS-QoL
Scale f rom: 0 (best: de-
lighted) to 6 (worst: terrible)
Follow-up: mean 4 weeks
37
(1 RCT)
⊕⊕©©
Lowa,b
- The mean change of quality
of lif e was -1.0
MD 0.1 higher
(0.56 lower to 0.76 higher)
Treatment withdrawals for
any reasonc
f ollow-up: mean 4 weeks
37
(1 RCT)
- Not reported Study populat ion
0 per 1000 0 fewer per 1000
(0 fewer to 0 fewer)
Cardiovascular adverse
eventsc
f ollow-up: mean 4 weeks
37
(1 RCT)
- Not reported Study populat ion
0 per 1000 0 fewer per 1000
(0 fewer to 0 fewer)
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Sexual adverse eventsc
f ollow-up: mean 4 weeks
37
(1 RCT)
- Not reported Study populat ion
0 per 1000 0 fewer per 1000
(0 fewer to 0 fewer)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; IPSS: Internat ional Prostate Symptom Score;MD: mean dif ference; IPSS-QoL: Internat ional Prostate Symptom Score - Quality of Life; RCT: randomised
controlled trial.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by one level for study lim itat ions: unclear risk of select ion, performance, detect ion, and report ing bias.
bDowngraded by one level for imprecision: conf idence interval crossed assumed threshold of clinically important dif f erence
of IPSS 3 and quality of lif e 0.5.
cTreatment withdrawal due to any reasons; cardiovascular adverse events; and sexual adverse events: no available data.
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Naftopidil compared to Eviprostat (phytotherapy) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)
Participants: men with lower urinary tract symptoms suggest ing benign prostat ic hyperplasia
Setting: l ikely outpat ients
Intervention: naf topidil
Comparator: Eviprostat
Outcomes of participants
(studies)
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects* (95% CI)
Risk with Eviprostat Risk difference with Nafto-
pidil
Urological symptom scores
assessed with: IPSS
Scale f rom: 0 (best: not at
all) to 35 (worst: almost al-
ways)
Follow-up: mean 6 weeks
49
(1 RCT)
⊕⊕⊕©
Moderatea
- The mean change of urolog-
ical symptom scores was 0.
4
MD 6.3 lower
(9.46 lower to 3.14 lower)
Quality of life
assessed with: IPSS-QoL
Scale f rom: 0 (best: de-
lighted) to 6 (worst: terrible)
Follow-up: mean 6 weeks
49
(1 RCT)
⊕⊕⊕©
Moderatea
- The mean change of quality
of lif e was 0
MD 1.5 lower
(2.36 lower to 0.64 lower)
Treatment withdrawals for
any reason
Follow-up: mean 6 weeks
49
(1 RCT)
⊕⊕©©
Very lowa,b
RR approximately 1 with
wide CI
Study populat ion
0 per 1000 0 fewer per 1000
(0 fewer to 0 fewer)
Treatment withdrawals due
to adverse events
Follow-up: mean 6 weeks
49
(1 RCT)
⊕⊕©©
Very lowa,b
RR approximately 1 with
wide CI
Study populat ion
0 per 1000 0 fewer per 1000
(0 fewer to 0 fewer)
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Cardiovascular adverse
eventsc
Follow-up: mean 6 weeks
49
(1 RCT)
- Not reported Study populat ion
0 per 1000 0 fewer per 1000
(0 fewer to 0 fewer)
Sexual adverse eventsc
Follow-up: mean 6 weeks
49
(1 RCT)
- Not reported Study populat ion
0 per 1000 0 fewer per 1000
(0 fewer to 0 fewer)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; IPSS: Internat ional Prostate Symptom Score;MD: mean dif ference; IPSS-QoL: Internat ional Prostate Symptom Score - Quality of Life; RCT: randomised
controlled trial.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by one level for study lim itat ions: unclear or high risk of bias in one or more domains.
bDowngraded by two level for imprecision: RR approximately 1 with wide conf idence interval and no events.
cCardiovascular adverse events and sexual adverse events: no available data.
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D I S C U S S I O N
Summary of main results
We included 22 unique studies with 2223 randomised participants
across four comparisons for short-term follow-up (up to 12weeks).
We found no longer-term data.
We were unable to compare naftopidil to placebo. The only avail-
able study did not report on any outcome relevant to this review
(Yamaguchi 1997).
Compared to tamsulosin, naftopidil may have had a similar effect
on urological symptom scores, QoL, and treatment withdrawals
for any reason (primary outcomes). It may have had a similar effect
on treatment withdrawals due to adverse event, AUR, surgical
intervention for LUTS/BPH, cardiovascular adverse events, and
sexual adverse events (secondary outcomes).
Findings were similar when comparing naftopidil to silodosin with
the exception of sexual adverse events, which were substantially
reduced by naftopidil. Naftopidil resulted in 123 fewer sexual ad-
verse events per 1000 men (95% CI 139 fewer to 80 fewer) com-
pared to silodosin.
The body of evidence comparing naftopidil to other ABs was lim-
ited. Compared to propiverine, naftopidil may have had similar
effects on urological symptom scores andQoL.We found no stud-
ies that reported other outcomes. Compared to Eviprostat, nafto-
pidil likely resulted in a clinically important reduction in urologi-
cal symptom scores and improved QoL. There were no treatment
withdrawals for any reason or due to adverse events.
We were unable to perform any of the predefined subgroup anal-
yses.
Overall completeness and applicability of
evidence
In this review update, we used up-to-date Cochrane methods and
added 16 news trials. Despite a large body of evidence informing
this review, the following issues deserve consideration.
• In contrast to the previous version of this review, we
identified one trial comparing naftopidil to placebo (Yamaguchi
1997). We could not use the study results because the study did
not report on any outcomes relevant to this review. This
information was confirmed by direct communication with the
study investigators.
• Our ability to assess the longer-term outcomes of naftopidil
compared to other drugs was limited given that all trials had a
short duration of follow-up of 12 weeks or less. Therefore, we
were unable to assess the longer-term efficacy and adverse effects
of naftopidil.
• Aside from three studies that used tamsulosin 0.4 mg
(Griwan 2014; Perumal 2015; Singh 2013), most studies
comparing naftopidil to tamsulosin 0.2 mg, which is lower than
the recommended dose in Western countries and is based on a
lower mean body size in Asian countries. Therefore, general
applicability of this body of evidence to non-Asian men is
uncertain.
• We were unable to determine the effect of naftopidil on
AUR or surgical interventions due to the lack of events in the
included studies. This related to the short follow-up period.
Additional information may have to be drawn from longer-term
observational studies.
• Although ABs such as naftopidil are commonly used in
combination with 5-ARIs, we found no eligible studies.
Quality of the evidence
We consistently downgraded the certainty of the evidence by one
or two levels to moderate or low. The most common reasons for
downgrading were study limitations (issues surrounding alloca-
tion concealment, blinding, and incomplete outcome data), clini-
cally important inconsistency (with high I2 values, which we were
unable to explain through secondary analyses), and imprecision
(wide CIs that crossed the assumed threshold of clinically impor-
tant difference or few events, or both). We also detected some
cases of potential publication bias due to the observed funnel plot
asymmetry.
Potential biases in the review process
Despite a comprehensive search strategy without any publication
or language restrictions, it is possible that we may have missed
relevant publications. A majority of studies originated from Japan
including other Asian countries (India, China, Korea). However,
this regional problemmight not be resolved in future study because
naftopidil was only approved these countries to treat men with
BPH. It is possible that some, in particular negative studies, were
published in non-indexed journals or presented at local meetings
only and therefore may have escaped our search. All Japanese and
Chinese literature were translated into English by two review au-
thors (MI, RP) with appropriate language skills. We used Google
translator to double check the translated data. However, the lack
of human double-data abstraction may be considered a potential
source of bias. We investigated reporting bias using funnel plots,
which showed no symmetry for IPSS (Figure 4) and asymmetry
for QoL in naftopidil and tamsulosin comparison arms (Figure 5).
We attempted to contact all the study authors on several occasions
seeking feedback. While we received additional information from
three study authors, others did not reply. This may represent a
source of bias. For cross-over trials, we tried to extract the data
from first period (before cross-over), as if the study were a parallel-
group trial, in accordance with Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011c). However, two cross-over
trials used the event rate to report individual adverse events, which
may result in a unit of analysis error (double counting) (Masuda
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2012; Singh 2013). For other cross-over trials, we used the num-
ber of participants initially randomised as a more conservative ap-
proach.
Agreements and disagreements with other
studies or reviews
Two systematic reviews and meta-analyses reported that nafto-
pidil had a similar effect on urological symptom scores and blad-
der outlet obstruction indices compared to other ABs (Fusco
2016; Yuan 2015). Along with a previous Cochrane systematic re-
view results (Garimella 2009), one systematic review reported that
naftopidil had comparable efficacy to tamsulosin and silodosin
(Castiglione 2014). Overall adverse events were reported as 2%
to 15%, which was comparable to tamsulosin (Castiglione 2014).
The incidence of sexual adverse events was less than compared
to silodosin (Castiglione 2014). However, both reviews only in-
cluded RCTs from Japan and those published in English language.
In addition, no meta-analysis was reported and the authors did
not rate the certainty of the evidence (Castiglione 2014; Garimella
2009). This updated Cochrane Review used rigorous methodol-
ogy, exhaustive literature search, and assessment of the certainty of
the evidence using GRADE, thereby providing the most reliable
evidence summary.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on moderate-to-low certainty evidence, the effect of nafto-
pidil appears similar to tamsulosinwith regards to urological symp-
tom scores, quality of life, and sexual adverse events.
Based on low-certainty evidence, the effect of naftopidil appears
similar to silodosin for urological symptom scores and quality of
life. However, it probably has fewer sexual adverse events com-
pared to silodosin based on moderate-certainty evidence. This in-
formation is important for the counselling of sexually active men.
Implications for research
Our knowledge could be improved by focus on the following is-
sues.
• Given that patients take alpha-blockers for extended periods
of time (typically years), there is a critical need for long-term
studies of safety and efficacy of naftopidil. Such studies would
also help to inform the outcome of acute urinary retention and
surgical interventions for benign prostatic hyperplasia.
• Several trials included in this review used suboptimal dose
of naftopidil (25 mg) and silodosin (4 mg). This may result in an
underestimate of both the beneficial effects and the potential
adverse events. Unfortunately, we were unable explore this and
other questions around possible subgroup effects (based on
patient age and baseline International Prostate Symptom Score)
in subgroup analyses.
• Most included studies had considerable methodological
limitations. It would be preferable if future studies applied
appropriate allocation concealment, blinding of all relevant
parties (participants, personnel, and outcome assessors), strove
for complete or near-complete follow-up, and had reporting
transparency.
• 5-alpha reductase inhibitors (e.g. finasteride and
dutasteride) and phosphodiesterase inhibitors (e.g. tadalafil) have
been used to treat lower urinary tract infections. Future studies
are needed to compare efficacy and adverse events between these
drugs and naftopidil.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Fujihara 2010
Methods Study design: parallel randomised clinical study
Setting/country: multicentre/Japan
Study dates: NR
Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men with LUTS with OAB symptoms
Exclusion criteria
• NR
Total number of participants randomised
• Screened: NR
• Eligible: 82
Group A (naftopidil)
• Number of participants randomised: 39
• Age: NR
• Prostate volume: NR
• PSA: NR
• IPSS (mean ± SD): 17.61 ± 5.8 (estimated from the figure)
• Qmax : NR
Group B (tamsulosin)
• Number of participants randomised: 43
• Age: NR
• Prostate volume: NR
• PSA: NR
• IPSS (mean ± SD): 15.72 ± 6.96 (estimated from the figure)
• Qmax : NR
Interventions Run-in period: none
Group A: naftopidil 50-75 mg once daily
Group B: tamsulosin 0.2 mg once daily
Duration: 12 weeks
Outcomes Primary outcomes
• Change from baseline in total score (questions 1-7) of IPSS, IPSS-QoL, VAS
• How measured: questionnaire
• Time of measurement: NR
• Time at reporting: baseline, 12 weeks
Secondary outcome
• NR
Safety outcome
• NR
Subgroup: none
Funding sources None
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Fujihara 2010 (Continued)
Declarations of interest NR
Notes Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “we performed a multi-center ran-
domised controlled study.”
Comment: randomisation stated but no in-
formation on method used was available;
therefore, selection bias was at unclear risk
of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear; abstract only
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear;
abstract only
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias was unclear; ab-
stract only
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear; abstract only
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear; abstract only
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear; abstract only
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear; abstract only
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Fujihara 2010 (Continued)
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear; abstract only
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear; abstract only
Selective reporting (reporting bias) Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of reporting
bias was unclear; abstract only
Other bias Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of other
sources of bias was unclear; abstract only
Gotoh 2005
Methods Study design: parallel randomised clinical study
Setting/country: multicentre (16 investigational sites)/Japan
Study dates: NR
Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men aged ≥ 50 years
• IPSS ≥ 8
• Qmax < 15 mL/s (voided volume ≥ 150 mL); prostate ≥ 20 mL
Exclusion criteria
• History of allergy to AB
• Treatment with antiandrogen drugs
• Current therapy with any AB
• Drugs with anticholinergic activity
• Significant history of orthostatic hypotension
• Concomitant neurological diseases
• Known or suspected neurogenic bladder dysfunction
• Carcinoma of the prostate or bladder
• Previous surgery for BPH or bladder neck obstruction
• History of recurrent UTI, or concomitant active UTI.
Total number of participants randomised
• Screened: 185
• Eligible: 144
Group A (naftopidil)
• Number of participants randomised: 69
• Age (years) (mean ± SD): 68.0 ± 7.2 (calculated from 95% CI 66.4 to 69.8)
• Prostate volume (mL) (mean ± SD): 29.0 ± 10.2 (calculated from 95% CI 27.2 to
32.0)
• PSA: NR
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Gotoh 2005 (Continued)
• IPSS (mean ± SD): 15.5 ± 5.7 (calculated from 95% CI 14.1 to 16.8)
• Qmax (mL/s) (mean ± SD): 9.3 ± 3.6 (calculated from 95% CI 8.4 to 10.1)
Group B (tamsulosin)
• Number of participants randomised: 75
• Age (years) (mean ± SD): 68.5 ± 6.8 (calculated from 95% CI 67.0 to 70.1)
• Prostate volume (mL) (mean ± SD): 33.6 ± 18.1 (calculated from 95% CI 29.5 to
37.7)
• PSA: NR
• IPSS (mean ± SD): 17.1 ± 6.18 (calculated from 95% CI 15.7 to 18.5)
• Qmax (mL/s) (mean ± SD): 8.8 ± 3.3 (calculated from 95% CI 8.1 to 9.6)
Interventions Run-in period: none
Group A: naftopidil 25 mg/day for 2 weeks, followed by 50 mg/day for 10 weeks
Group B: tamsulosin 0.2 mg/day for 12 weeks
Duration: 12 weeks
Outcomes Primary outcomes
• Change from baseline in the total score (questions 1-7) of IPSS, Qmax , PVR
• How measured: IPSS questionnaire, uroflowmetry, transabdominal US
• Time of measurement: baseline; 2, 4, 8, 12 weeks
• Time of reporting: baseline, 12 weeks
Secondary outcomes
• Change from baseline in mean flow rate, IPSS voiding score, IPSS storage score,
IPSS-QoL
• How measured: IPSS questionnaire, uroflowmetry
• Time of measurement: baseline; 2, 4, 8, 12 weeks
• Time of reporting: baseline, 12 weeks
Safety outcomes
• Adverse effect
• BP changes
• How measured; NR, systolic/diastolic BP
• Time of measurement: baseline, 12 weeks
• Time of reporting: baseline, 12 weeks
Subgroup: none
Funding sources NR
Declarations of interest None
Notes Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “prospective, randomised con-
trolled trial”
Comment: randomisation stated but no in-
formation on method used was available;
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Gotoh 2005 (Continued)
therefore, selection bias was at unclear risk
of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias unclear
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
High risk Comment: 21/90 (23.3%) participants in
naftopidil group and 20/95 (21.0%) par-
ticipants in tamsulosin group not included
in analysis; owing to a reasonable number
of participants lost to follow-up (> 20%),
risk of attrition bias was high
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Selective reporting (reporting bias) Unclear risk Comment: review outcomes are well de-
scribed but protocol was not published
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias found;
therefore, risk of other bias was low
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Griwan 2014
Methods Study design: parallel randomised clinical study
Setting/country: single institute/India
Study dates: NR
Participants Ethnicity: Indian
Inclusion criteria
• Aged ≥ 45 years
• Daytime frequency > 8, nocturnal frequency > 2
• Qmax 5-15 mL/s (150 mL voided volume), PVR < 150 mL
• IPSS > 13, IPSS bother score > 3
Exclusion criteria
• Previous prostate surgery
• Severe visceral disease
• Postural hypotension
• Neurogenic bladder dysfunction, suspected prostate cancer, urethral stricture
disease, history of pelvic irradiation, bladder neck disease, acute bacterial prostatitis,
acute UTI, urolithiasis, history of concomitant medication that could alter the voiding
pattern before inclusion (calcium antagonist, monoamine oxidase inhibitors, or
anticholinergic drugs)
• Active haematuria
• Renal insufficiency (serum creatinine > 2.0 mg/dL), severe hepatic impairment
(transaminases > 2 times the upper normal limit or total bilirubin > 1.5 mg/dL, or
both)
• People taking antipsychotic medications, insulin-dependent diabetes mellitus,
history of severe heart disease (myocardial infarction or cerebrovascular accident in the
previous 6 months), ascertained or suspected hypersensitivity to tamsulosin and
naftopidil
Total number of participants randomised
• Screened: NR
• Eligible: 120
Group A (naftopidil)
• Number of participants randomised: 60
• Age: NR
• Prostate volume (mL) (mean ± SD): 56.81 ± 6.45
• PSA: NR
• IPSS (mean ± SD): 21.31 ± 4.04
• Qmax (mL/s) (mean ± SD): 10.25 ± 1.34
Group B (tamsulosin)
• Number of participants randomised: 60
• Age: NR
• Prostate volume (mL) (mean ± SD): 57.73 ± 7.33
• PSA: NR
• IPSS (mean ± SD): 21.95 ± 4.46
• Qmax (mL/s) (mean ± SD): 9.36 ± 1.21
Interventions Run-in period: none
Group A: naftopidil 75 mg/day
Group B: tamsulosin 0.4 mg/day
Duration: 3 months
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Griwan 2014 (Continued)
Outcomes Primary outcomes
• Change from baseline in the total score (questions 1-7) of IPSS, QoL, Qmax ,
prostate volume, PVR
• How measured: questionnaire, Qmax (Laborie Urocap III uroflowmeter), prostate
volume (US), PVR (NR)
• Time of measurement: baseline; 1, 3 months
• Time of reporting: baseline; 1, 3 months
Secondary outcome
• NR
Safety outcome
• NR
Subgroup: none
Funding sources NR
Declarations of interest None
Notes Language of publication: English
No predefined secondary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated, simple, ran-
domised analysis”
Comment: sequence generation method
was provided.
Allocation concealment (selection bias) Unclear risk Comment: insufficient information about
allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patients included in the study
as well as the doctor conducting the study
were blinded to the drug being adminis-
tered and the group allocation.”
Comment: blinding of participants and
study personnel ensured
Blinding of outcome assessment (detection
bias)
Susceptible
Low risk Quote: “The patients included in the study
as well as the doctor conducting the study
were blinded to the drug being adminis-
tered and the group allocation.”
Comment: blinding of participants and
study personnel ensured
Blinding of outcome assessment (detection
bias)
Low risk Comment: objective outcomes not likely
affected by lack of blinding
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Griwan 2014 (Continued)
Not susceptible
Incomplete outcome data (attrition bias)
IPSS/QoL
Low risk Quote: “no dropouts during the duration
of the study.”
Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Quote: “no dropouts during the duration
of the study.”
Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Quote: “no dropouts during the duration
of the study.”
Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: study did not address these out-
comes.
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Low risk Quote: “no dropouts during the duration
of the study.”
Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Sexual adverse events
Low risk Quote: “no dropouts during the duration
of the study.”
Comment: all randomised participants
were included in analysis
Selective reporting (reporting bias) Unclear risk Comment: review outcomes were well de-
scribed but protocol was not published
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias found;
therefore, risk of other bias was low
Hanyu 2010
Methods Study design: prospective randomised clinical study
Setting/country: multicentre (4 centres)/Japan
Study dates: May 2005 to May 2008
Participants Ethnicity: Japan
Inclusion criteria
• Men aged ≥ 50 years at first visit
• Total IPSS ≥ 8, QoL index score ≥ 2
• Prostate volume ≥ 20 mL
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Hanyu 2010 (Continued)
• PVR < 100 mL
Exclusion criteria
• People with prostate cancer, bladder cancer, neurogenic bladder, urethral stricture,
or UTI
• Administration of hormonal agents for BPH within 1 month before study
• Administration of drugs considered to affect urination within 2 weeks before
study (e.g. alpha-blocker, beta-blocker, anticholinergic agents, cholinergic agonist,
antidepressant)
• Serious liver or kidney disorder, cardiac disorder
Total number of participants randomised
• Screened: NR
• Eligible: 105
Group A (naftopidil)
• Number of participants randomised: 55
• Age (years) (mean ± SD): 70.5 ± 5.8
• Prostate volume (mL) (mean ± SD): 40.2 ± 16.3
• PSA: NR
• IPSS (mean ± SD): 14.8 ± 5.7
• Qmax (mL/s) (mean ± SD): 9.5 ± 3.4
Group B (tamsulosin)
• Number of participants randomised: 50
• Age (years) (mean ± SD): 70.9 ± 5.8
• Prostate volume (mL) (mean ± SD): 41.0 ± 19.3
• PSA: NR
• IPSS (mean ± SD): 13.5 ± 5.0
• Qmax (mL/s) (mean ± SD): 8.6 ± 3.5
Interventions Run-in period: none
Group A: naftopidil 50 mg/day
Group B: tamsulosin 0.2 mg/day
Duration: 12 weeks
Outcomes Primary outcomes
• IPSS, QoL Index
• How measured: questionnaire
• Time of measurement: before; 4, 12 weeks
• Time of reporting: before; 4, 12 weeks
Secondary outcomes
• Qmax , PVR/clinical efficacy evaluated based on IPSS and QoL
• How measured: NR/according to “criteria for treatment efficacy in BPH” in the
“voiding dysfunction clinical trial guideline” proposed by the Japanese Urological
Association
• Time of measurement: before; 4, 12 week
• Time of reporting: before; 4, 12 weeks
Safety outcome
• Adverse effect
• How measured: NR
• Time of measurement: NR
• Time of reporting: not specified but assumed to be last follow-up (12 weeks)
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Subgroup: none
Funding sources NR
Declarations of interest NR
Notes Language of publication: Japanese
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random assignment”, “using a ran-
dom number table”
Comment: method of random sequence
generation had low risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias was unclear
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
High risk Comment: 19/55 (34.5%) participants in
naftopidil group and 18/50 (36.0%) par-
ticipants in tamsulosin group were not in-
cluded in the analysis
Owing to a large proportion of participants
lost to follow-up (> 20%), risk of attrition
bias was high
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
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Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: no cardiovascular adverse
events reported in naftopidil group, but 1/
40 (2.5%) reported in tamsulosin group
Owing to insufficient information to per-
mit judgement, risk of attrition bias was
unclear
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Selective reporting (reporting bias) Unclear risk Comment: protocol not published.
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias found;
therefore, risk of other bias was low
Ikemoto 2003
Methods Study design: randomised cross-over clinical study
Setting/country: 3 hospitals in single institute/Japan
Study dates: March 2000 to April 2002
Participants Ethnicity: Japan
Inclusion criteria
• IPSS ≥ 8, Qmax < 12 mL/s (150 mL voiding)
• if prior BPH medication, 1-month washout period
Exclusion criteria: NR
Total number of participants randomised
• Screened: NR
• Eligible: 96
Group A (naftopidil)
• Number of participants randomised: 43
• Age (years) (mean ± SD): 66.6 ± 7.6
• Prostate volume (mL) (mean ± SD): 38.9 ± 11.8
• PSA: NR
• IPSS (mean ± SD): 17.4 ± 6.0
• Qmax (mL/s) (mean ± SD): 9.3 ± 4.0
Group B (tamsulosin)
• Number of participants randomised: 53
• Age (years) (mean ± SD): 63.8 ± 9.1
• Prostate volume (mL) (mean ± SD): 32.7 ± 9.4
• PSA: NR
• IPSS (mean ± SD): 16.8 ± 7.2
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• Qmax (mL/s) (mean ± SD): 9.1 ± 6.0
Interventions Run-in period: none
Group A: naftopidil 25 mg/day for first 2 weeks, then 50 mg once daily for 6 weeks
then tamsulosin 0.2 mg for 8 weeks
Group B: tamsulosin 0.2 mg for 8 weeks then naftopidil 25 mg for 2 weeks, then 50
mg for 6 weeks
Duration: 8 weeks (additional 8 weeks after cross-over/no washout)
Outcomes Primary outcomes
• IPSS, QoL, Qmax , PVR
• How measured: questionnaire, uroflow, abdominal US
• Time of measurement: baseline, cross-over, end of treatment
• Time of reporting: baseline, cross-over, end of treatment
Secondary outcome
• NR
Safety outcome
• Safety
• How measured: questionnaire, uroflowmetry, abdominal US
• Time of measurement: NR
• Time of reporting: NR
Subgroup: none
Funding sources NR
Declarations of interest NR
Notes Language of publication: English
No predefined primary or secondary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly divided with the enve-
lope method”
Comment: method of random sequence
generation was at low risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
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Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias was unclear
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
High risk Comment: 12/43 (27.9%) participants in
silodosin group and 18/53 (33.9%) partic-
ipants in naftopidil group not included in
analysis
Owing to a large proportion of participants
lost to follow-up (> 20%), risk of attrition
bias was high
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Selective reporting (reporting bias) Unclear risk Comment: protocol not published.
Other bias Unclear risk Comment: no washout period
Ju 2002
Methods Study design: double-blind parallel randomised clinical study
Setting/country: single institute/China
Study dates: June to November 2011
Participants Ethnicity: NR (China)
Inclusion criteria
• Men aged 50-75 years with BPH
• IPSS ≥ 13
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• PSA ≤ 4 ng/mL, Qmax 5-15 mL/s when urine volume > 150 mL
Exclusion criteria
• Prostate cancer, hypotension, severe heart disease, lung disease, liver diseases, or
renal diseases
• People who underwent or needed to receive invasive intervention for BPH
• Other diseases such as neurogenic bladder, bladder neck obstruction, bladder
cancer, benign bladder tumour, bladder diverticular, urethral stricture, or active UTI
• Mental disorder
• People with poor compliance
• Doctor believed person could not take naftopidil
Total number of participants randomised
• Screened: 80
• Eligible: 80
Group A (naftopidil)
• Number of participants randomised: 40
• Age (years) (mean ± SD): 62.5 ± 5.26
• Prostate volume: NR
• PSA: NR
• IPSS (mean ± SD): 18.79 ± 4.8
• Qmax (mL/s) (mean ± SD): 11.24 ± 3.22
Group B (tamsulosin)
• Number of participants randomised: 40
• Age (years) (mean ± SD): 66.5 ± 5.8
• Prostate volume: NR
• PSA: NR
• IPSS (mean ± SD): 19.71 ± 4.7
• Qmax (mL/s) (mean ± SD): 11.32 ± 3.29
Interventions Run-in period: none
Group A: naftopidil 25 mg once daily
Group B: tamsulosin 0.2 mg once daily
Duration: 6 weeks
Outcomes Primary outcomes
• IPSS, Qmax
• How measured: questionnaire, Qmax (NR)
• Time of measurement: baseline, 6 weeks
• Time of reporting: baseline, 6 weeks
Secondary outcomes
• QoL, PVR, prostate volume
• How measured: questionnaire, PVR (US), prostate volume (US)
• Time of measurement: baseline, 6 weeks
• Time of reporting: baseline, 6 weeks
Safety outcome
• Adverse reactions
• How measured: adverse reactions (record)
• Time of measurement: baseline, 6 weeks
• Time of reporting: baseline, 6 weeks
Subgroup: none
50Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ju 2002 (Continued)
Funding sources NR
Declarations of interest NR
Notes Language of publication: Chinese
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: owing to insufficient informa-
tion, risk of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quotes: “double blinded”
Comment: no description who was
blinded, owing to insufficient information,
risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Quotes: “double blinded”
Comment: no description who was
blinded, owing to insufficient information,
risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Low risk Comment: 1/40 (2.5%) participants in
naftopidil group and 2/40 (5%) partici-
pants in tamsulosin group were not in-
cluded in the analysis, owing to the small
number of participants lost to follow-up,
risk of attrition bias was low
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
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Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: study did not address this out-
come.
Selective reporting (reporting bias) High risk Comment: protocol was not published and
QoL (secondary outcome) was not re-
ported
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias found;
therefore, risk of other bias was low
Kwon 2018
Methods Study design: parallel randomised clinical study
Setting/country: multicentre/Korea
Study dates: January 2015 to July 2015
Participants Ethnicity: NR (Korea)
Inclusion criteria
• 94 men who had been taking tamsulosin for > 8 weeks; however, men who persist
more than 3 points of OABSS, especially more than 2 points of OABSS question 3
Exclusion criteria
• Treated with 5-alpha reductase inhibitors within 6 months or anticholinergics
within 8 weeks of study commencement
• Aged < 40 years, with a lower OABSS after than before treatment
• With an abnormal urinalysis (RBC > 5/HPF, WBC > 5/HPF) or liver (an AST/
ALT ratio > 100) or renal function (creatinine > 2 mg/dL), or who developed a severe
adverse effect during treatment, such as, orthotropic hypotension or an allergic reaction
Total number of participants randomised
• Screened: NR
• Eligible: 94
Group A (naftopidil)
• Number of participants randomised: 49
• Age (years) (mean ± SD): 66.0 ± 6.3
• Prostate volume (mL) (mean ± SD): 36.8 ± 14.6
• PSA: NR
• IPSS (mean ± SD): 16.9 ± 6.2
• Qmax (mL/s) (mean ± SD): 17.5 ± 25.6
Group B (tamsulosin)
• Number of participants randomised: 45
• Age (years) (mean ± SD): 64.8 ± 7.7
• Prostate volume (mL) (mean ± SD): 37.5 ± 22.4
• PSA: NR
• IPSS (mean ± SD): 19.1 ± 7.2
• Qmax (mL/s) (mean ± SD): 15.5 ± 8.4
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Interventions Run-in period: none
Group A: naftopidil 75 mg/day for 8 weeks
Group B: tamsulosin 0.2 mg once daily for 8 weeks
Duration: 8 weeks
Outcomes Primary outcomes
• IPSS, OABSS, Qmax , PVR
• How measured: questionnaires, uroflowmetry, PVR (NR)
• Time of measurement: baseline, 6 weeks
• Time of reporting: baseline, end of treatment
Secondary outcome
• NR
Safety outcome
• NR
Subgroup: none
Funding sources Financial support from Donga ST Pharm Korea, Inc.
Declarations of interest NR
Notes Language of publication: English
No predefined primary or secondary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-based by randomiza-
tions”
Comment: method of random sequence
generation at low risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias was unclear
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
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Incomplete outcome data (attrition bias)
IPSS/QoL
Unclear risk Comment: number of participants were
not provided or included in analysis, owing
to insufficient information topermit judge-
ment, risk of attrition bias was unclear
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Selective reporting (reporting bias) Unclear risk Comment: our review outcomes were well
described, Author provided raw data but
protocol was not published
Other bias High risk Quote: “Ninety-four patients that hadbeen
taking tamsulosin for more than 8 weeks,
however, patients who persist more than 3
points of OABSS, especially more than 2
points of OABSS question 3, were enrolled
and divided into two groups.”
Comment: enrolled participants who had
insufficient symptom improvement
Li 2007
Methods Study design: parallel randomised clinical study
Setting/country: multicentre (9 centre)/China
Study dates: September 2002 to December 2003
Participants Ethnicity: NR (China)
Inclusion criteria
• Men with BPH/LUTS aged 50-75 years
• Total IPSS ≥ 13
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• Prostate volume > 20 mL, Qmax < 15 mL/s, PVR < 60 mL
Exclusion criteria
• Other diseases, such as neurogenic bladder, bladder stone, urethral stone, prostate
cancer, urethral stricture, or active UTI
• Men who underwent or needed to receive invasive intervention for BPH
• Severe diabetes, heart disease, lung disease, liver diseases, or renal diseases
• Received pharmacological treatment for BPH in past 1 month
• Without a history of postural hypotension
• Mental disorder
Total number of participants randomised
• Screened: 906
• Eligible: 906
Group A (naftopidil)
• Number of participants randomised: 126
• Age (years) (mean ± SD): 67.7 ± 5.5
• Prostate volume (mL) (mean ± SD): 38.1 ± 15.4
• PSA (ng/mL) (mean ± SD): 2.5 ± 1.4
• IPSS (mean ± SD): 20.6 ± 5.4
• Qmax (mL/s) (mean ± SD): 11.1 ± 3.1
Group B (tamsulosin)
• Number of participants randomised: 138
• Age (years) (mean ± SD): 66.8 ± 5.4
• Prostate volume (mL) (mean ± SD): 43.1 ± 17.7
• PSA (ng/mL) (mean ± SD): 2.4 ± 1.1
• IPSS (mean ± SD): 21.1 ± 5.6
• Qmax (mL/s) (mean ± SD): 10.7 ± 2.8
Other active: terazosin; doxazosin; finasteride; epristeride; cernilton
Interventions Run-in period: none
Group A: naftopidil 25 mg once daily
Group B: tamsulosin 0.2 mg once daily
Other active: terazosin 2 mg once daily; doxazosin 4 mg once daily; finasteride 5 mg
once daily; epristeride 5 mg twice daily; cernilton 70 mg twice daily
Duration: 12 months
Outcomes Primary outcomes
• IPSS, QoL Index, Qmax , PVR
• How measured: questionnaire (IPSS, QoL), Qmax (NR), PVR (US)
• Time of measurement: before; 3, 6, 9, 12 months
• Time of reporting: before; 3, 6, 9, 12 months
Secondary outcome
• NR
Safety outcome
• NR
Subgroup: none
Funding sources Chinese National Programs for Science and Technology Development
Declarations of interest NR
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Notes Language of publication: Chinese
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: owing to insufficient informa-
tion, risk of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “randomised, open-label, con-
trolled multicenter study”
Comment: open-label trial; therefore, risk
of performance bias was high
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Quote: “randomised, open-label, con-
trolled multicenter study”
Comment: open-label trial; therefore, risk
of performance bias was high
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
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Selective reporting (reporting bias) High risk Comment: protocol was not published and
QoL (secondary outcome) was not re-
ported
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias found;
therefore, risk of other bias was low
Masuda 2012
Methods Study design: randomised cross-over clinical study
Setting/country: multicentre/Japan
Study dates: November 2009 to March 2011
Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men with LUTS/BPH, prostate volume ≥ 20 cm3
• IPSS ≥ 8, QoL score ≥ 3, clinical diagnosis of BPH, aged ≥ 50 years, no prior
treatment for BPH
Exclusion criteria
• Organ disorder other than BPH (e.g. prostate cancer, bladder cancer, prostatitis,
urethral stricture), previous TURP or minimally invasive treatment, indwelling
catheter or urethral self-catheterisation, active UTI, neurogenic cystitis
• Nervous system disease as complication
• Administration of hormonal agents for BPH within 6 month before study,
administration of alpha-blocker within 6 weeks before study, other people deemed
unsuitable by attending physician
Total number of participants randomised
• Screened: NR
• Eligible: 92
Group A (naftopidil)
• Number of participants randomised: 48
• Age (years) (mean ± SD): 68.5 ± 5.7
• Prostate volume (mL) (mean ± SD): 45.7 ± 17.8
• PSA: NR
• IPSS (mean ± SD): 17.6 ± 5.0
• Qmax (mL/s) (mean ± SD): 9.3 ± 4.9
Group B (silodosin)
• Number of participants randomised: 44
• Age (years) (mean ± SD): 66.5 ± 5.6
• Prostate volume (mL) (mean ± SD): 38.8 ± 13.1
• PSA: NR
• IPSS (mean ± SD): 18.6 ± 5.5
• Qmax (mL/s) (mean ± SD): 8.0 ± 3.7
Interventions Run-in period: NR
Group A: naftopidil 50-75 mg once daily for 2 weeks, then 75 mg once daily for 4 weeks
Group B: silodosin 2-4 mg twice daily for 2 weeks, then 4 mg twice daily for 4 weeks
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Duration: 6 weeks (additional 6 weeks after cross-over, no washout)
Outcomes Primary outcome
• IPSS
• How measured: questionnaire, uroflowmetry (NR), US (PVR)
• Time of measurement: baseline, 6 weeks
• Time of reporting: baseline, 6 weeks
Secondary outcomes
• IPSS subscore, QoL, OABSS, Qmax , PVR, questionnaire to evaluate participant
drug preference
• How measured: questionnaire, uroflowmetry (NR), US (PVR)
• Time of measurement: baseline, 6 weeks
• Time of reporting: baseline, 6 weeks
Safety outcome
• Adverse events
Subgroup:NR
Funding sources NR
Declarations of interest NR
Notes Language of publication: Japanese
This crossover trial had no washout period because authors considered treatment in-
terruption to be disadvantageous to participants. 6 weeks with first drug, followed by
another 6 weeks with second drug. Data extracted only from the first period (i.e. at 6
weeks) like a parallel group trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients enrolled consecutively
and assigned alternately.”
Comment: method of random sequence
generation at high risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias was unclear
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Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
High risk Comment: 14/48 (29.1%) participants in
naftopidil group and 14/44 (31.8%) par-
ticipants in silodosin group were not in-
cluded in analysis
Owing to a reasonable number of partici-
pants lost to follow-up (> 20%), risk of at-
trition bias was high
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Selective reporting (reporting bias) Unclear risk Comment: review outcomes were well de-
scribed, but protocol was not published
Other bias High risk Comment: drug administration times were
different between groups
Masumori 2009
Methods Study design: parallel randomised clinical study
Setting/country: multicentre (17 centres)/Japan
Study dates: March 2005 to March 2006
Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men with LUTS/BPH, aged 51-79 years, IPSS ≥ 8
Exclusion criteria
• History of urinary retention, PVR ≥ 200 mL, hydronephrosis or renal
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impairment caused by bladder outlet obstruction (or both)
• Intractable haematuria, prostate cancer, history of prostatic surgery, neurogenic
bladder, urethral stricture, and chronic bacterial prostatitis
• Receiving alpha-blocker or antiandrogen (or both) in past 3 months
Total number of participants randomised
• Screened: NR
• Eligible: 95
Group A (naftopidil)
• Number of participants randomised: 48
• Age (years) (mean ± SD): 64.5 ± 7.7
• Prostate volume (mL) (mean ± SD): 35.9 ± 15.3
• PSA: NR
• IPSS (mean ± SD): 15.0 ± 5.9
• Qmax (mL/s) (mean ± SD): 10.7 ± 5.3
Group B (tamsulosin)
• Number of participants randomised: 47
• Age (years) (mean ± SD): 65.2 ± 7.5
• Prostate volume (mL) (mean ± SD): 34.4 ± 13.7
• PSA: NR
• IPSS (mean ± SD): 17.8 ± 5.7
• Qmax (mL/s) (mean ± SD): 11.1 ± 4.8
Interventions Run-in period: none
Group A: naftopidil 50 mg/day
Group B: tamsulosin 0.2 mg/day
Duration: 12 weeks
Outcomes Primary outcomes
• Incidence of ejaculatory disorders, erectile dysfunction
• How measured: questionnaire (evaluate ejaculatory volume), IIEF-5
• Time of measurement: baseline and 12 week
• Time of reporting: baseline, 12 weeks
Secondary outcomes
• Qmax , PVR, clinical efficacy evaluated based on IPSS and QoL
• How measured: IPSS, IPSS-QoL, uroflowmetry (NR), PVR (NR)
• Time of measurement: baseline, 12 weeks
• Time of reporting: baseline, 12 weeks
Safety outcome
• Adverse events
• How measured: NR
• Time of measurement: NR
• Time of reporting: not specified but assumed to be last follow-up (12 weeks)
Subgroup: none
Funding sources NR
Declarations of interest NR
Notes Language of publication: English
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “permutated block design”
Comment: method of random sequence
generation at low risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of selection bias was unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias was unclear
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
High risk Comment: 10/48 (20.8%) participants in
naftopidil group and 12/47 (25.5%) par-
ticipants in tamsulosin group were not in-
cluded in the analysis
Owing to a reasonable number of partici-
pants lost to follow-up (> 20%), risk of at-
trition bias was high
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: 3/48 (6%) participants in
naftopidil group and 1/47 (2%) partici-
pants in tamsulosin group were not in-
cluded in the analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Low risk Comment: 3/48 (6%) participants in the
naftopidil group and 1/47 (2%) partici-
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pants in the tamsulosin group were not in-
cluded in the analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
Incomplete outcome data (attrition bias)
Sexual adverse events
Low risk Comment: 3/48 (6%) participants in the
naftopidil group and 1/47 (2%) partici-
pants in the tamsulosin group were not in-
cluded in the analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
Selective reporting (reporting bias) Unclear risk Comment: review outcomes are well de-
scribed, but protocol was not published
Other bias High risk Quote: “the IPSS and QOL index at base-
line were significantly lower in the nafto-
pidil group than in the tamsulosin group.”
Comment: baseline imbalance
Matsukawa 2017
Methods Study design: parallel open-label randomised clinical study
Setting/country: multicentre/Japan
Study dates: May 2012 to September 2013
Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men aged ≥ 50 years
• Total IPSS ≥ 8, IPSS-QoL score ≥ 3, total OABSS ≥ 3, ≥ 1 urinary urgency
episodes/week
• Prostate volume ≥ 20 mL on transabdominal ultrasonography
• Qmax < 15 mL/s at a voided volume of ≥ 100 mL and PVR < 150 mL
Exclusion criteria
• Received oral treatment with a1-blockers, anticholinergic agents, 5-alpha
reductase inhibitors, antidepressants, antianxiety agents, or sex hormonal agents
• Neurogenic bladder dysfunction, bladder calculi or active UTI, severe cardiac
disease, renal dysfunction (serum creatinine levels≥ 2 mg/dL) or hepatic dysfunction
(AST and ALT concentrations more than twice normal values)
• Prostate cancer confirmed by prostate biopsy
Total number of participants randomised
• Screened: 350
• Eligible: 350
Group A (naftopidil)
• Number of participants randomised: 175
• Age (years) (mean ± SD): 70.3 ± 7.8
• Prostate volume (mL) (mean ± SD): 38.6 ± 14.8
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• PSA (ng/mL) (mean ± SD): 3.0 ± 3.1
• IPSS (mean ± SD): 18.9 ± 6.1
• Qmax (mL/s) (mean ± SD): 8.4 ± 3.0
Group B (silodosin)
• Number of participants randomised: 175
• Age (years) (mean ± SD): 70.6 ± 7.8
• Prostate volume (mL) (mean ± SD): 39.6 ± 16.7
• PSA (ng/mL) (mean ± SD): 3.0 ± 3.1
• IPSS (mean ± SD): 18.8 ± 6.2
• Qmax (mL/s) (mean ± SD): 8.2 ± 3.6
Interventions Run-in period: NR
Group A: naftopidil 50 mg/day for 4 weeks, then 75 mg/day for 8 weeks
Group B: silodosin 4 mg/day for 4 weeks, then 8 mg/day for 8 weeks
Duration: 12 weeks
Outcomes Primary outcomes
• IPSS, QoL Index, OABSS
• How measured: questionnaire
• Time of measurement: baseline; 4, 12 weeks
• Time of reporting: baseline; 4, 12 weeks
Secondary outcomes
• Qmax , PVR
• How measured: uroflowmetry, PVR (NR)
• Time of measurement: baseline; 4, 12 weeks
• Time of reporting: baseline; 4, 12 weeks
Safety outcome
• Adverse reactions
• How measured: NR
• Time of measurement: NR
• Time of reporting: NR
Subgroup:NR
Funding sources NR
Declarations of interest NR
Notes Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomizations using a random
number table at the study center.”
Comment: method of random sequence
generation at low risk of bias
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Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “prospective, open label, ran-
domised, multicenter study.”
Comment: open-label trial; no blinding;
therefore, risk of performance bias was high
Blinding of outcome assessment (detection
bias)
Susceptible
Low risk Quote: “The data obtained were de-iden-
tified and analysed independently by 2 of
our research group members not involved
in this study.”
Comment: open-label trial; no blinding;
therefore, risk of performance bias was high
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Unclear risk Comment: 18/175 (10.2%) participants in
naftopidil group and 18/175 (10.2%) par-
ticipants in silodosin group were not in-
cluded in analysis but missing outcome
data balanced in numbers across interven-
tion groups with similar reasons
Owing to the moderated number of par-
ticipants lost to follow-up (> 10%), risk of
attrition bias was low
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all participants were enrolled in
analysis.
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all participants were enrolled in
analysis.
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Low risk Comment: all participants were enrolled in
analysis.
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
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Selective reporting (reporting bias) Unclear risk Comment: review outcomes are well de-
scribed, but protocol was not published
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias could
be found; therefore, risk of other bias was
low
Momose 2007
Methods Study design: cross-over randomised clinical study
Setting/country: single centre/Japan
Study dates: February 2002 to December 2003
Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men with LUTS with BPH
Exclusion criteria
• Drugs that might affect urinary excretion function, prostate cancer, neurogenic
bladder suspected, UTI, chronic bacterial prostatitis, etc.
Total number of participants randomised
• Screened: NR
• Eligible: 45
Group A (naftopidil)
• Number of participants randomised: 20
• Age (years) (mean ± SD): 65.3 ± 5.5
• Prostate volume (mL) (mean ± SD): 30.7 ± 13.8
• PSA: NR
• IPSS (mean ± SD): 19.6 ± 7.0
• Qmax (mL/s) (mean ± SD): 9.4 ± 3.2
Group B (tamsulosin)
• Number of participants randomised: 25
• Age (years) (mean ± SD): 68.2 ± 7.7
• Prostate volume (mL) (mean ± SD): 47.2 ± 22.6
• PSA: NR
• IPSS (mean ± SD): 18.4 ± 6.9
• Qmax (mL/s) (mean ± SD): 9.2 ± 3.3
Interventions Run-in period: NR
Group A: naftopidil 50 mg/day for 4 weeks, then tamsulosin 0.2 mg/day for 4 weeks
Group B: tamsulosin 0.2 mg/day for 4 weeks, then naftopidil 50 mg/day for 4 weeks
Duration: 28 days (additional 28 days after cross-over/no washout)
Outcomes Primary outcomes
• Total IPSS, storage symptoms, voiding symptoms, QoL score
• How measured: questionnaire
• Time of measurement: baseline; 4, 8 weeks
• Time of reporting: baseline; 4, 8 weeks
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Secondary outcome
• NR
Safety outcome
• Safety
• How measured: NR
• Time of measurement: NR
• Time of reporting: NR
Subgroup:NR
Funding sources NR
Declarations of interest NR
Notes Language of publication: English
No predefined primary and secondary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: owing to insufficient informa-
tion, risk of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias was unclear
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
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Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Selective reporting (reporting bias) Unclear risk Comment: review outcomes were well de-
scribed, but protocol was not published
Other bias Unclear risk Comment: no washout period
Nishino 2006
Methods Study design: cross-over randomised clinical study
Setting/country: single centre/Japan
Study dates: NR
Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men with LUTS secondary to BPH
Exclusion criteria
• Total IPSS < 7 or Qmax >15 mL/s
• Neurogenic disorders, UTI, urinary retention, bladder tumour, or bladder stones
Total number of participants randomised
• Screened: NR
• Eligible: 34
Group A (naftopidil)
• Number of participants randomised: 17
• Age (years) (mean ± SD): 73.2 ± 4.1
• Prostate volume (mL) (mean ± SD): 20.6 ± 3.7
• PSA: NR
• IPSS (mean ± SD): 20.7 ± 4.3
• Qmax (mL/s) (mean ± SD): 9.7 ± 0.4
Group B (tamsulosin)
• Number of participants randomised: 17
• Age (years) (mean ± SD): 71.5 ± 4.5
• Prostate volume (mL) (mean ± SD): 18.9 ± 2.8
• PSA: NR
• IPSS (mean ± SD): 20.1 ± 2.7
• Qmax (mL/s) (mean ± SD): 10.1 ± 0.7
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Interventions Run-in period: NR
Group A: naftopidil 50 mg/day for 4 weeks, then tamsulosin 0.2 mg/day for 4 weeks
Group B: tamsulosin 0.2 mg/day for 4 weeks, then naftopidil 50 mg/day for 4 weeks
Duration: 4 weeks: data analysis (4 weeks before cross-over, 1-week washout, and addi-
tional 4 weeks after cross-over)
Outcomes Primary outcomes
• Improvement in LUTS and QoL, values of uroflowmetry, and PFS
• How measured: IPSS questionnaire, uroflowmetry, and PFS
• Time of measurement: baseline, 8 weeks
• Time of reporting: baseline, 8 weeks
Secondary outcome
• NR
Safety outcome
• Adverse events
• How measured: NR
• Time of measurement: NR
• Time of reporting: NR
Subgroup:NR
Funding sources Gifu University, Japan
Declarations of interest None
Notes Language of publication: English
No predefined primary and secondary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: owing to insufficient informa-
tion, risk of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double-blind”
Comment: no description who was
blinded, owing to insufficient information,
risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Quote: “double-blind”
Comment: no description who was
blinded, owing to insufficient information,
risk of performance bias was unclear
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Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Sexual adverse events
Low risk Comment: all randomised participants
were included in analysis
Selective reporting (reporting bias) Unclear risk Comment: review outcomes are well de-
scribed, but protocol was not published
Other bias Low risk Comment: 1-week washout period.
Perumal 2015
Methods Study design: prospective parallel randomised
Setting/country: single centre/India
Study dates: September 2011 to June 2013
Participants Ethnicity: NR (India)
Inclusion criteria
• Men aged > 50 years, clinical symptoms of BPE, LUTS, with or without raised
PVR urine
Exclusion criteria
• Untreated UTI, palpable nodule in the prostate, associated upper urinary tract
changes and prostate size > 60 mL
Total number of participants randomised
• Screened: NR
• Eligible: 60
Group A (naftopidil)
• Number of participants randomised: 30
• Age (years) (mean ± SD): 59.9 ± 5.5
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• prostate volume: NR
• PSA: NR
• IPSS (mean ± SD): 19.97 ± 2.53
• Qmax (mL/s) (mean ± SD): 8.63 ± 1.38
Group B (tamsulosin)
• Number of participants randomised: 30
• Age (years) (mean ± SD): 60.1 ± 5.0
• Prostate volume: NR
• PSA: NR
• IPSS (mean ± SD): 21.3 ± 2.84
• Qmax (mL/s) (mean ± SD): 8.37 ± 1.22
Interventions Run-in period: NR
Group A: naftopidil 50 mg once daily
Group B: tamsulosin 0.4 mg once daily
Duration: 30 days
Outcomes Primary outcomes
• IPSS, Qmax , PVR
• How measured: questionnaire, uroflowmetry (Qmax ), abdominal US
• Time of measurement: baseline, 15/30 days
• Time of reporting: baseline, 15/30 days
Secondary outcome
• NR
Safety outcome
• NR
Subgroup:NR
Funding sources Mahatma Gandhi Medical College and Research Institute
Declarations of interest None
Notes Language of publication: English
No predefined secondary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “who presented on odd numbered
days were placed in Group A, patients who
presented on evennumber dayswere placed
in study Group B.”
Comment: method of random sequence
generation at high risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias was unclear
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Selective reporting (reporting bias) Unclear risk Comment: adverse events were not re-
ported and protocol was not published
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias could
be found; therefore, risk of other bias was
low
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Methods Study design: randomised, open-label, controlled
Setting/country: Kobe University School or other collaborating institutions/Japan
Study dates: July 2007 to March 2011
Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men with BPH/LUTS, total IPSS 8 points, QoL index 3 points, Qmax < 15 mL/
s, prostate volume 20 mL
• Men with BPH/LUTS without history of using any alpha blocker (hereafter,
drug-naive group) or men with BPH/LUTS who had continued to use tamsulosin 0.2
mg once daily for at least 3 months and wanted to switch the medication to another
oral drug (hereafter, drug-switching group).
Exclusion criteria
• Other diseases such as prostate cancer, bladder tumour, cystolithiasis, prostatitis,
urethral stricture, or active UTI
• Complication of neurogenic bladder or disease suspected of neurogenic bladder
• Participation in study deemed inappropriate by their primary physician
Total number of participants randomised
• Screened: NR
• Eligible: 121
Group A (naftopidil)
• Number of participants randomised: 60
• Age (years) (mean ± SD): 70.50 ± 6.58
• Prostate volume (mL) (mean ± SD): 39.39 ± 25.96
• PSA: NR
• IPSS (mean ± SD): 17.56 ± 6.73
• Qmax (mL/s) (mean ± SD): 11.13 ± 6.53
Group B (silodosin)
• Number of participants randomised: 61
• Age (years) (mean ± SD): 70.98 ± 6.69
• Prostate volume (mL) (mean ± SD): 38.24 ± 12.94
• PSA: NR
• IPSS (mean ± SD): 17.53 ± 5.4
• Qmax (mL/s) (mean ± SD): 9.87 ± 4.50
Interventions Run-in period: NR
Group A: naftopidil 50 mg once daily
Group B: silodosin 4 mg twice daily
Duration: 8 consecutive weeks
Outcomes Primary outcomes
• Total IPSS, subtotal IPSS of storage symptoms, subtotal IPSS of voiding
symptoms, postmicturition symptoms, QoL index
• How measured: IPSS questionnaire
• Time of measurement: baseline; 4, 8 weeks
• Time of reporting: baseline; 4, 8 weeks
Secondary outcome
• NR
Safety outcome
• Safety
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• How measured: adverse events
• Time of measurement: NR
• Time of reporting: NR
Subgroup
• Drug-naive/drug-switching
Funding sources NR
Declarations of interest None
Notes Language of publication: English
No predefined primary, secondary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned, using a ran-
dom number table”
Comment: method of random sequence
generation at low risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “randomised, open-label, con-
trolled multicenter study”
Comment: open-label trial; no blinding;
therefore, risk of performance bias was high
Blinding of outcome assessment (detection
bias)
Susceptible
High risk Quote: “randomised, open-label, con-
trolled multicenter study”
Comment: open-label trial; no blinding;
therefore, risk of performance bias was high
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Low risk Comment: 4/60 (6.7%) participants in
naftopidil group and 5/61 (8.2%) partici-
pants in silodosin group were not included
in analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
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Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: 3/60 (5.0%) participants in
naftopidil group and 2/61 (3.3%) partici-
pants in silodosin group were not included
in analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Low risk Comment: 3/60 (5.0%) participants in
naftopidil group and 2/61 (3.3%) partici-
pants in silodosin group were not included
in analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
Incomplete outcome data (attrition bias)
Sexual adverse events
Low risk Comment: 3/60 (5.0%) participants in
naftopidil group and 2/61 (3.3%) partici-
pants in silodosin group were not included
in analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
Selective reporting (reporting bias) Low risk Comment: protocol (UMIN000008331)
was published. While results were shown
separately in participants with drug naive
and switching group, reviewoutcomeswere
well described
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias could
be found; therefore, risk of other bias was
low
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Methods Study design: prospective parallel randomised clinical study
Setting/country: single institution/India
Study dates: October 2010 to April 2012
Participants Ethnicity: NR (India)
Inclusion criteria
• Men with BPH with IPSS > 8 or > 3 points for frequency, nocturia, and urgency
on IPSS
• Prostate volume > 15 mL, or peak flow rate < 10 mL for a voided volume > 150
mL
Exclusion criteria
• Hypersensitivity to alpha-blockers; history of prostatic or urethral surgery; men
with absolute indications for prostate surgery
• Neurological disorders; neurogenic bladder; and cardiovascular, renal, or hepatic
dysfunction
Total number of participants randomised
• Screened: NR
• Eligible: 110
Group A (naftopidil)
• Number of participants randomised: 55
• Age (years) (mean): 61.69
• Prostate volume (mL) (mean): 31.38
• PSA: NR
• IPSS (mean): 21.06
• Qmax (mL/s) (mean): 10.62
Group B (tamsulosin)
• Number of participants randomised: 55
• Age (years) (mean): 61.15
• Prostate volume (mL) (mean): 30.01
• PSA: NR
• IPSS (mean): 21.53
• Qmax (mL/s) (mean): 9.41
Interventions Run-in period: NR
Group A: naftopidil 50 mg once daily
Group B: tamsulosin 0.4 mg once daily
Duration: 12 weeks
Outcomes Primary outcomes
• IPSS, Qmax , PVR, mean flow rate
• How measured: questionnaire, uroflowmetry, US
• Time of measurement: baseline; 2, 4, 6, 12 weeks
• Time of reporting: baseline; 2, 4, 6, 12 weeks
Secondary outcome
• NR
Safety outcome
• Adverse effects
• How measured: NR
• Time of measurement: NR
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• Time of reporting: NR
Subgroup:NR
Funding sources NR
Declarations of interest NR
Notes Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised per a
randomizations table generated.”
Comment: method of random sequence
generation at low risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: personnel were blinded but the
study did not address the blind of partici-
pants
Blinding of outcome assessment (detection
bias)
Susceptible
Low risk Quote: “The randomizations/allocation of
patient group(s) and patient data per pro-
tocol was recorded by a resident (second
author) who was blinded to the study med-
ication. The protocol, concept, design, and
intellectual content for the current study
was drafted, conceived, and contributed by
the first author who was also blinded to rel-
evant patient data at the time of its inter-
pretation and statistical analysis.”
Comment: risk of detection bias was low.
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Low risk Comment: 5/55 (9.0%) participants in
naftopidil group and 4/55 (7.2%) partic-
ipants in tamsulosin group were not in-
cluded in analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
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Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Low risk Comment: 5/55 (9.0%) participants in
naftopidil group and 4/55 (7.2%) partic-
ipants in tamsulosin group were not in-
cluded in analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Low risk Comment: 5/55 (9.0%) participants in
naftopidil group and 4/55 (7.2%) partic-
ipants in tamsulosin group were not in-
cluded in analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
Incomplete outcome data (attrition bias)
Sexual adverse events
Low risk Comment: 5/55 (9.0%) participants in
naftopidil group and 4/55 (7.2%) partic-
ipants in tamsulosin group were not in-
cluded in analysis
Owing to the small number of participants
lost to follow-up, risk of attrition bias was
low
Selective reporting (reporting bias) Unclear risk Comment: review outcomes are well de-
scribed, but protocol was not published
Other bias Low risk Study appeared free of other source.
Comment: no other sources of bias could
be found; therefore, risk of other bias was
low
Ub 2016
Methods Study design: randomised cross-over study
Setting/country: multicentre/Japan
Study dates: December 2009 to March 2013
Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men with OAB and BPH who met the following criteria and not administered
medication (except herbal preparation) for urinary disorder: IPSS ≥ 2, QoL score ≥ 2,
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OABSS ≥ 3 (urgency score ≥ 2)
Exclusion criteria
• History of hypersensitivity to naftopidil, tamsulosin, or solifenacin
• Angle-closure glaucoma
• Pylos, duodenum or bowel obstruction, or paralytic ileus, gastric atony, or
intestinal atony
• Severe myasthenia, serious cardiac disease, severe hepatic dysfunction (Child-
Pugh classification C), Parkinson’s disease
Total number of participants randomised
• Screened: NR
• Eligible: 59
Group A (naftopidil)
• Number of participants randomised: NR
• Age (years) (mean ± SD): 74.7 ± 8.0
• Prostate volume: NR
• PSA: NR
• IPSS (mean ± SD): 17.4 ± 6.7
• Qmax : NR
Group B (tamsulosin)
• Number of participants randomised: NR
• Age (years) (mean ± SD): 71.9 ± 8.3
• Prostate volume: NR
• PSA: NR
• IPSS (mean ± SD): 18.1 ± 5.4
• Qmax : NR
Interventions Run-in period: NR
Group A: naftopidil 75 mg/day
Group B: tamsulosin 0.2 mg/day + solifenacin 5 mg/day
Duration: 8 weeks (additional 8 weeks after cross-over, no washout: authors judged that
evaluation without washout period would be feasible)
Outcomes Primary outcomes
• IPSS, QoL index, OABSS, PVR, voided volume, Qmax , participant questionnaire
(which drug participant preferred with reason)
• How measured: questionnaire, uroflowmetry where possible
• Time of measurement: 8 weeks, Qmax (whenever possible)
• Time of reporting: baseline, 8 weeks (16 weeks reported but not extracted; see
note)
Secondary outcome
• NR
• How measured: NR
• Time of measurement: NR
• Time of reporting: baseline, 8 weeks (16 weeks reported but not extracted; see
note)
Safety outcome
• Adverse effect
• How measured: NR
• Time of measurement: NR
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• Time of reporting: baseline, 8 weeks (16 weeks reported but not extracted; see
note)
Subgroup:NR
Funding sources NR
Declarations of interest NR
Notes Language of publication: Japanese
Reason for why data was not extracted:
This cross-over trial had no washout period because authors judged that evaluation
without washout period would be feasible
This cross-over trial did not report data on the within-person differences (paired analysis)
. 59 were randomised, of whom 28 dropped out. 5 withdrew due to participant’s own
reason; 12 not eligible (excluded after randomisation); 8 withdrew due to adverse effects;
3 withdrew due to lack of improvement or symptom getting worse
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: owing to insufficient informa-
tion, risk of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Quote: “envelope method”
Comment: method of allocation conceal-
ment at low risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “comparison of 1 tablet and 2
tablets”
Comment: participants may have known
which medication they are taking therefore
risk of performance bias was high
Blinding of outcome assessment (detection
bias)
Susceptible
High risk Quote: “comparison of 1 tablet and 2
tablets”
Comment: study did not address blinding
of personnel but assume not done; there-
fore, risk of detection bias was high
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
High risk Comment: 28/59 (47%) participants were
not included in the analysis
Owing to a reasonable number of partici-
pants lost to follow-up (> 20%), risk of at-
trition bias was high
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Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Unclear risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Unclear risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: not available (cross-over trial)
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
High risk Comment: 28/59 (47%) participants were
not included in the analysis
Owing to a reasonable number of partici-
pants lost to follow-up (> 20%), risk of at-
trition bias was high
Incomplete outcome data (attrition bias)
Sexual adverse events
High risk Comment: 28/59 (47%) participants were
not included in the analysis
Owing to a reasonable number of partici-
pants lost to follow-up (> 20%), risk of at-
trition bias was high
Selective reporting (reporting bias) Unclear risk Comment: results section stated that
uroflowmetry data were dropped from
treatment efficacy analysis due to large
amount of missing data and protocol was
not published
Other bias Unclear risk Comment: no washout period
Ukimura 2008
Methods Study design: parallel randomised clinical study
Setting/country: multicentre/Japan
Study dates: June 2004 to July 2007
Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men aged ≥ 50 years, number of nocturia ≥ 2
• IPSS ≥ 8, QoL index ≥ 3
• Residual urine volume < 50 mL (evaluated by US estimation)
• Maximum voiding flow rate < 15 mL/s (preferably with a urination volume ≥
150 mL)
• Prostate volume < 50 mL
Exclusion criteria
• Prostate cancer, acute prostatitis, or narrowing of the urinary tract
• Received prostate surgery, balloon dilation, urinary tract stenting, hyperthermia,
or pelvic radiation before beginning of study
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• Catheterised or were performing intermittent self-catheterisation
• Marked night-time polyuria
• Active UTI (urinary WBC count ≥ 5/HPF)
• Suspected to have neurogenic bladder or other neurological disorders
• Severe ischaemic heart disease, cerebrovascular disorders, liver dysfunction, or
kidney dysfunction
• Hypotension (systolic BP ≤ 100 mmHg and diastolic BP ≤ 60 mmHg),
orthostatic hypotension, or severe hypertension
• Hypersensitivity to naftopidil or tamsulosin
• Administered a hormonal drug for prostatic hyperplasia within 1 month prior to
the beginning of study
• Administered a drug that might affect urination other than hormonal drugs for
the treatment of prostatic hyperplasia within 2 weeks prior to the beginning of study
• Judged by the attending physicians to be inappropriate as participants.
Total number of participants randomised
• Screened: NR
• Eligible: 81
Group A (naftopidil)
• Number of participants randomised: NR
• Age (years) (mean ± SD): 69.6 ± 6.8
• Prostate volume (mL) (mean ± SD): 24.4 ± 6.9
• PSA: NR
• IPSS (mean ± SD): 17.2 ± 6.4
• Qmax (mL/s) (mean ± SD): 9.9 ± 5.5
Group B (tamsulosin)
• Number of participants randomised: NR
• Age (years) (mean ± SD): 68.8 ± 8.2
• Prostate volume (mL) (mean ± SD): 26.7 ± 7.9
• PSA: NR
• IPSS (mean ± SD): 18.9 ± 6.6
• Qmax (mL/s) (mean ± SD): 9.6 ± 4.8
Interventions Run-in period: NR
Group A: naftopidil 50 mg once daily
Group B: tamsulosin 0.2 mg once daily
Duration: 6-8 weeks
Outcomes Primary outcomes
• IIPSS, QoL, urination volume, Qmax , mean flow rate (Qmean), residual urine
volume, and urination time
• How measured: questionnaire, uroflowmetry
• Time of measurement: baseline; 2, 6-8 weeks
• Time of reporting: baseline; 2, 6-8 weeks
Secondary outcome
• NR
Safety outcome
• NR
Subgroup:NR
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Funding sources NR
Declarations of interest NR
Notes Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “birthday was an odd number,”
“birthday was an even number”
Comment: method of random sequence
generation at high risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias was unclear
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
High risk Comment: 22/81 (24.7%) participants
were not included in the analysis
Owing to a reasonable number of partici-
pants lost to follow-up (> 20%), risk of at-
trition bias was high
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
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Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Selective reporting (reporting bias) Unclear risk Comment: protocol was not published and
Adverse events were not addressed
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias could
be found; therefore, risk of other bias was
low
Yamaguchi 2013
Methods Study design: parallel randomised clinical study
Setting/country: multicentre/Japan
Study dates: December 2007 to November 2010
Participants Ethnicity: Japan
Inclusion criteria
• Men with BPH aged ≥ 50 years
• Significant LUTS and deteriorated QoL
• IPSS ≥ 8 and QoL score ≥ 3
Exclusion criteria
• Established prostate cancer
• Neurogenic bladder and any other complications that affect micturitional status
• Men who underwent prostate surgery, intervention, or radiotherapy
Total number of participants randomised
• Screened: 109
• Eligible: 109
Group A (naftopidil)
• Number of participants randomised: 51
• Age (years) (mean ± SD): 70.0 ± 7.0
• Prostate volume (mL) (mean ± SD): 39.5 ± 18.0
• PSA (ng/mL) (mean ± SD): 3.9 ± 3.5
• IPSS (mean ± SD): 18.9 ± 7.0
• Qmax (mL/s) (mean ± SD): 9.9 ± 5.3
Group B (tamsulosin)
• Number of participants randomised: 58
• Age (years) (mean ± SD): 69.3 ± 7.8
• Prostate volume (mL) (mean ± SD): 33.2 ± 21.2
• PSA (ng/mL) (mean ± SD): 2.8 ± 3.3
• IPSS (mean ± SD): 16.9 ± 5.5
• Qmax (mL/s) (mean ± SD): 10.4 ± 5.0
83Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yamaguchi 2013 (Continued)
Interventions Run-in period: none
Group A: naftopidil 75 mg/day
Group B: silodosin 8 mg/day
Duration: 12 weeks
Outcomes Primary outcomes
• IPSS, QoL Index, IIEF-5, Qmax (mL/s), PVR (mL)
• How measured: questionnaire, uroflowmetry, PVR (NR)
• Time of measurement: before; 4, 8, 12 weeks after treatment
• Time of reporting: IPSS, QoL, IIEF: before; 4, 8, 12 weeks after treatment;
Qmax , PVR: before; 12 weeks after treatment
Secondary outcome
• NR
Safety outcome
• NR
Subgroup: none
Funding sources NR
Declarations of interest None
Notes Language of publication: English
No predefined primary, secondary outcomes
Data (IPSS, QoL, treatment withdrawal, AUR, surgical intervention, cardiovascular
adverse events) were given by contact with study author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random number table envelope
method”
Comment: method of random sequence
generation at low risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of detection bias was unclear
84Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yamaguchi 2013 (Continued)
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
High risk Comment: 13/51 (25.5%) participants in
naftopidil group and 17/58 (29.3%) par-
ticipants in silodosin group were not in-
cluded in analysis
Owing to a reasonable number of partici-
pants lost to follow-up (> 20%), risk of at-
trition bias was high
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
We received the data after contacting the
study author.
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
We received the data after contacting the
study author
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Low risk Comment: all randomised participants
were included in analysis
We received the data after contacting the
study author.
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Low risk Comment: all randomised participants
were included in analysis
We received the data after contacting the
study author.
Incomplete outcome data (attrition bias)
Sexual adverse events
Low risk Comment: all sexually active participants
(21/44 (47%) participants in naftopidil
group; 23/53 (44%) participants in silo-
dosin group) who were randomised were
included in analysis
Selective reporting (reporting bias) Unclear risk Comment: data (treatment withdrawal,
AUR, and surgical intervention) were given
by contact with study author, but protocol
was not published
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias could
be found; therefore, risk of other bias was
low
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Methods Study design: single-blind, randomised parallel clinical study
Setting/country: single centre/Japan
Study dates: NR
Participants Ethnicity: NR (Japan)
Inclusion criteria
• IPSS ≥ 8, Qmax < 12 mL/s, prostate volume ≥ 15 mL
• Obstructive (or equivocal) condition on International Continence Society
nomogram as assessed in a pressure/flow study.
Exclusion criteria
• Complete urinary retention
• Prostatic cancer, prostatitis, and urethral stricture
• Severe cardiac or cerebrovascular disorders, hepatic disorders, renal dysfunction,
or orthostatic hypotension
• Medication with anticholinergics, other ABs, beta-agonists, or beta-antagonists
Total number of participants randomised
• Screened: NR
• Eligible: 49
Group A (naftopidil)
• Number of participants randomised: 36
• Age (years) (mean ± SD): 67.5 ± 8.2
• Prostate volume (mL) (mean ± SD): 29.7 ± 14.9
• PSA: NR
• IPSS (mean ± SD): 15.4 ± 5.7
• Qmax (mL/s) (mean ± SD): 9.8 ± 4.4
Group B (Eviprostat)
• Number of participants randomised: 13
• Age (years) (mean ± SD): 69.0 ± 6.5
• Prostate volume (mL) (mean ± SD): 29.5 ± 15.9
• PSA: NR
• IPSS (mean ± SD): 16.0 ± 6.9
• Qmax (mL/s) (mean ± SD): 8.5 ± 4.4
Interventions Run-in period: 1 weeks
Group A: naftopidil 25 mg once daily for 2 weeks, then 50 mg once daily for 2 weeks,
and then 75 mg once daily for 2 weeks
Group B: Eviprostat 6 tablets daily
Duration: 6 weeks
Outcomes Primary outcomes
• IPSS, QoL, Qmax , PVR, urodynamic parameters
• How measured: questionnaire, uroflowmetry, catheterisation, video-urodynamic
studies
• Time of measurement: baseline, 4-6 weeks (endpoint)
• Time of reporting: baseline, 4-6 weeks (endpoint)
Secondary outcome
• NR
Safety outcome
• NR
Subgroup: none
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Funding sources NR
Declarations of interest NR
Notes Language of publication: English
No predefined primary or secondary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “using an envelope indicating one
of the two groups.”
Comment: method of random sequence
generation at low risk of bias
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “single-blind, randomised con-
trolled study.”
Comment: no description who was
blinded, single blinding; therefore, risk of
performance bias was high
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Quote: “single-blind, randomised con-
trolled study”
Comment: no description who was
blinded, single blinding; therefore, risk of
detection bias was high
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
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Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Selective reporting (reporting bias) Unclear risk Comment: protocol was not published.
Other bias Unclear risk Comment: “observation run-in period of 1
week”
Yokoyama 2009
Methods Study design: prospective randomised controlled clinical study
Setting/country: 2 centres/Japan
Study dates: June 2004 to March 2007
Participants Ethnicity: NR/Japan
Inclusion criteria
• Men aged ≥ 50 years
• IPSS ≥ 8, 2-day frequency volume chart showing ≥ 1 episode/day of urinary
urgency
• Daytime voiding frequency ≥ 8 episodes/day, night-time voiding frequency ≥ 1
episode/night
• PVR ≤ 50 mL
• Men with elevated serum PSA level (> 10 ng/mL) were confirmed as having BPH
before the treatment by transrectal US-guided prostate sextant biopsies
Exclusion criteria: NR
Total number of participants randomised
• Screened: NR
• Eligible: 58
Group A (naftopidil)
• Number of participants randomised: 19
• Age (years) (mean ± SD): 69.1 ± 8.3
• Prostate volume (mL) (mean ± SD): 26.6 ± 12.3
• PSA: NR
• IPSS (mean ± SD): 18.2 ± 5.7
• Qmax (mL/s) (mean ± SD): 9.8 ± 4.0
Group B (propiverine hydrochloride)
• Number of participants randomised: 18
• Age (years) (mean ± SD): 70.9 ± 6.7
• Prostate volume (mL) (mean ± SD): 25.3 ± 7.7
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• PSA: NR
• IPSS (mean ± SD): 18.2 ± 7.0
• Qmax (mL/s) (mean ± SD): 9.5 ± 3.1
Interventions Run-in period: NR
Group A: naftopidil 50 mg/day
Group B: propiverine hydrochloride 20 mg/day
Group C: naftopidil 50 mg/day + propiverine hydrochloride 20 mg/day
Duration: 4 weeks
Outcomes Primary outcomes
• IPSS, QoL Index, urinary urgency, voiding frequency, daily void volume, urinary
urgency, urinary incontinence, Qmax , PVR
• How measured: questionnaire, Urgency Perception Scale, frequency volume
charts, uroflowmetry, transabdominal ultrasonography
• Time of measurement: before, 4 weeks
• Time of reporting: before, 4 weeks
Secondary outcome
• NR
Safety outcome
• Safety
• How measured: NR
• Time of measurement: NR
• Time of reporting: NR
Subgroup:NR
Funding sources NR
Declarations of interest None
Notes Language of publication: English
3-arm comparison: naftopidil vs propiverine versus naftopidil + propiverine (not eligible
for our review)
No predefined primary or secondary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: owing to insufficient informa-
tion, risk of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Comment: owing to insufficient informa-
tion, risk of allocation concealment was un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
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Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: owing to insufficient informa-
tion, risk of performance bias was unclear
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Unclear risk Comment: 8/66 (12.1%) randomised par-
ticipants were not included in analysis
Owing tomoderate number of participants
lost to follow-up (> 10%), risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Incomplete outcome data (attrition bias)
Sexual adverse events
Unclear risk Comment: owing to insufficient informa-
tion to permit judgement, risk of attrition
bias was unclear
Selective reporting (reporting bias) Unclear risk Comment: protocol was unpublished.
Other bias Low risk Study appeared free of other sources of bias.
Comment: no other sources of bias could
be found; therefore, risk of other bias was
low
Yokoyama 2011
Methods Study design: parallel randomised clinical study
Setting/country: 2 centres/Japan
Study dates: NR
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Participants Ethnicity: NR (Japan)
Inclusion criteria
• Men with LUTS aged 50-80 years, IPSS ≥ 8
Exclusion criteria
• Received oral treatment with 5-alpha reductase inhibitors, anticholinergic drugs,
antidepressants, or sex hormonal drugs
• Neurogenic bladder dysfunction, bladder calculi, or active UTI, or had severe
cardiac disease, renal dysfunction (serum creatinine > 2 mg/dL), or hepatic dysfunction.
Total number of participants randomised
• Screened: 136
• Eligible: 136
Group A (naftopidil)
• Number of participants randomised: 46
• Age (years) (mean ± SD): 69.1 ± 1.2
• Prostate volume (mL) (mean ± SD): 35.0 ± 3.1
• PSA: NR
• IPSS (mean ± SD): 17.4 ± 0.8
• Qmax (mL/s) (mean ± SD): 8.63 ± 0.5
Group B (tamsulosin)
• Number of participants randomised: 45
• Age (years) (mean ± SD): 71.5 ± 1.1
• Prostate volume (mL) (mean ± SD): 32.5 ± 2.0
• PSA: NR
• IPSS (mean ± SD): 18.0 ± 1.1
• Qmax (mL/s) (mean ± SD): 8.56 ± 0.5
Group C (silodosin)
• Number of participants randomised: 45
• Age (years) (mean ± SD): 70.2 ± 0.9
• Prostate volume (mL) (mean ± SD): 33.3 ± 2.3
• PSA: NR
• IPSS (mean ± SD): 18.7 ± 0.7
• Qmax (mL/s) (mean ± SD): 9.03 ± 0.6
Interventions Run-in period: NR
Group A: naftopidil 50 mg once daily
Group B: tamsulosin 0.2 mg once daily
Group C: silodosin 4 mg twice daily
Duration: 12 weeks
Outcomes Primary outcomes
• IPSS, QoL Index, IIEF-5, ejaculation, Qmax , PVR
• How measured: questionnaire, ultrasonography (PVR), uroflowmetry (NR)
• Time of measurement: before; 1, 3 months after treatment ended
• Time of reporting: before; 1, 3 months after treatment ended
Secondary outcome
• NR
Safety outcome
• Safety
• How measured: NR
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• Time of measurement: NR
• Time of reporting: NR
Subgroup:NR
Funding sources NR
Declarations of interest NR
Notes Language of publication: English
No predefined primary or secondary outcomes, data (IPSS, QoL, AUR, and surgical
intervention) from study author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomly assigned”
Comment: study author reply, “Computer
generated central randomization”
Allocation concealment (selection bias) Low risk Comment: study author reply, “Computer
generated central randomization”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: study author reply, “partici-
pants were not blinded”
Blinding of outcome assessment (detection
bias)
Susceptible
Unclear risk Comment: study did not address this out-
come.
Blinding of outcome assessment (detection
bias)
Not susceptible
Low risk Comment: objective outcomes not likely
affected by lack of blinding
Incomplete outcome data (attrition bias)
IPSS/QoL
Unclear risk Comment: 14/136 (10.2%) participants
who were randomised were not included in
analyses
owing to the moderate number of partici-
pants lost to follow-up (> 10%), risk of at-
trition bias was unclear
Incomplete outcome data (attrition bias)
Treatment withdrawal for any reason
Low risk Comment: all randomised participants
were included in analysis
Incomplete outcome data (attrition bias)
Treatment withdrawal due to adverse
events
Unclear risk Comment: 14/136 (10.2%) participants
who were randomised were not included in
analyses
Owing to the moderate number of partici-
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pants lost to follow-up (> 10%), risk of at-
trition bias was unclear
Incomplete outcome data (attrition bias)
AUR/Surgical intervention
Unclear risk Comment: 14/136 (10.2%) participants
who were randomised were not included in
analyses
Owing to the moderate number of partici-
pants lost to follow-up (> 10%), risk of at-
trition bias was unclear
Incomplete outcome data (attrition bias)
Cardiovascular adverse events
Unclear risk Comment: 14/136 (10.2%) participants
who were randomised were not included in
analyses
Owing to the moderate number of partici-
pants lost to follow-up (> 10%), risk of at-
trition bias was unclear
Incomplete outcome data (attrition bias)
Sexual adverse events
Low risk Comment: analyses limited to men who
were sexually active (15/46 (32.6%) par-
ticipants in naftopidil group, 17/45 (37.
8%) participants in tamsulosin group, 17/
45 (37.7%) participants in silodosin group;
all sexually active)
All participants were included in analysis.
Selective reporting (reporting bias) Unclear risk Comment: protocol was not published.
Other bias High risk Comment: drug administration times were
different between group. Baseline imbal-
ance in PVR; silodosin group had much
higher PVR, which may have underesti-
mated the effect size
AB: alpha blocker; ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUR: acute urinary retention; BP: blood pressure;
BPE: benign prostatic enlargement; BPH: benign prostatic hyperplasia; CI: confidence interval; HPF: high power field; IIEF:
International Index of Erectile Function; IPSS: International Prostate Symptom Score; IPSS-QoL: International Prostate Symptom
Score - Quality of Life; LUTS: lower urinary tract infection; NR: not reported; OAB: overactive bladder; OABSS: Overactive
Bladder Symptom Score; PFS: pressure flow study; PSA: prostate-specific antigen; PVR: postvoid residual; QoL: quality of life;
Qmax : maximal flow rate; RBC: red blood cell; s: second; TURP: transurethral resection of prostate; US: ultrasound; UTI: urinary
tract infection; VAS: visual analogue scale; WBC: white blood cell.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Carson 2017 Commentary
Hayashi 2002 Ineligible study design (non-randomised trial)
Hiroshi 2011 Ineligible comparator (naftopidil 25 mg vs 50 mg vs 75 mg)
Ikemoto 2010 Review
Maruyama 2006 Ineligible comparator (naftopidil 25-75 mg vs naftopidil 25-75 mg + oxybutynin hydrochloride 4-8 mg or
naftopidil 25-75 mg + propiverine hydrochloride 10-20 mg)
Sakai 2011 Ineligible comparator (naftopidil 50 mg morning medication vs naftopidil 50 mg evening medication)
Tsuritani 2010 Ineligible comparator (naftopidil 75 mg once daily in the evening vs 25 mg 3 times daily)
Yamaguchi 1992 Ineligible outcomes (symptom improvement rates, outcome not measured)
Yamaguchi 1997 Ineligible outcomes (symptom improvement rates, outcome not measured)
Yokoyama 2006 Ineligible comparator (naftopidil 75 mg/day vs 25 mg/day)
Characteristics of studies awaiting assessment [ordered by study ID]
NCT01203371
Methods Randomised, double-blind, parallel group design
Participants Inclusion criteria
• Aged 50-90 years
• Signs and symptoms of BPH
• IPSS ≥ 10
• Prostate volume ≥ 20 mL
• PVR > 150 mL
Exclusion criteria
• History of allergy to an alpha-blocker
• Treatment with antiandrogen drugs
• Drugs with anticholinergic activity
• Significant history of orthostatic hypotension
• Concomitant neurological diseases
• Known or suspected neurogenic bladder dysfunction
• Carcinoma of prostate or bladder
• Previous surgery for BPH or bladder neck obstruction
• History of recurrent UTI
• Concomitant active UTI
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NCT01203371 (Continued)
Interventions Group A: naftopidil 25 mg for 2 weeks then 50 mg for 10 weeks
Group B: tamsulosin 0.4 mg/day for 12 weeks
Outcomes Primary outcome
• IPSS (2, 4, 8, 12 weeks)
Secondary outcome
• Adverse effect (2, 4, 8, 12 weeks)
Notes Funding sources: Apsen Farmaceutica S.A.
Publication status: NCT01203371 (final publication status has not been clarified)
NCT01922375
Methods Placebo-controlled, randomised, double-blind, double-dummy, parallel-group, fixed-dose design
Participants Inclusion criteria
• Aged ≥ 45 years with BPH
Exclusion criteria
• Uncontrolled blood pressure
• Hepatic or renal dysfunction
• Prostate cancer
• Received treatments for BPH using other alpha-blockers within 2 weeks
Interventions Group A: naftopidil dose 2
Group B: placebo
Group C: naftopidil dose 1
Outcomes Primary outcome
• IPSS change (baseline to 12 weeks (end of treatment))
Secondary outcome
• IPSS, uroflowmetry, LUTS-GAQ (baseline to 12 weeks (end of the treatment))
Notes Funding sources: Dong-A Pharmaceutical Co., Ltd.
Publication status: NCT01922375 (final publication status has not been clarified)
BPH: benign prostatic hyperplasia; IPSS: International Prostate Symptom Score; LUTS-GAQ: Lower Urinary Tract Symptoms Global
Assessment Question; PVR: postvoid residual; UTI: urinary tract infection.
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D A T A A N D A N A L Y S E S
Comparison 1. Naftopidil versus tamsulosin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 International Prostate Symptom
Score
12 965 Mean Difference (IV, Random, 95% CI) 0.47 [-0.09, 1.04]
2 International Prostate Symptom
Score-Quality of Life
11 878 Mean Difference (IV, Random, 95% CI) 0.11 [-0.09, 0.30]
3 Treatment withdrawals for any
reason
8 668 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.64, 1.34]
4 Treatment withdrawals due to
adverse events
9 735 Risk Ratio (M-H, Random, 95% CI) 1.82 [0.72, 4.61]
5 Acute urinary retention 3 272 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.23, 2.86]
6 Surgical intervention 2 171 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Cardiovascular adverse events 9 824 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.52, 1.80]
8 Sexual adverse events 5 397 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.24, 1.22]
Comparison 2. Naftopidil versus silodosin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 International Prostate Symptom
Score
5 652 Mean Difference (IV, Random, 95% CI) 1.04 [-0.78, 2.85]
2 International Prostate Symptom
Score-Quality of Life
5 652 Mean Difference (IV, Random, 95% CI) 0.21 [-0.23, 0.66]
3 Treatment withdrawals for any
reason
4 659 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.52, 1.23]
4 Treatment withdrawals due to
adverse events
5 738 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.35, 1.51]
5 Acute urinary retention 2 180 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Surgical intervention 2 180 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Cardiovascular adverse events 5 808 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.39, 2.44]
8 Sexual adverse events 4 348 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.06, 0.42]
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Comparison 3. Naftopidil versus propiverine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 International Prostate Symptom
Score
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 International Prostate Symptom
Score-Quality of Life
1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 4. Naftopidil versus Eviprostat
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 International Prostate Symptom
Score
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 International Prostate Symptom
Score-Quality of Life
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Treatment withdrawals for any
reason
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Treatment withdrawals due to
adverse events
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Naftopidil versus tamsulosin, Outcome 1 International Prostate Symptom
Score.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 1 Naftopidil versus tamsulosin
Outcome: 1 International Prostate Symptom Score
Study or subgroup Naftopidil Tamsulosin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fujihara 2010 39 -3.77 (5.65) 43 -3.31 (6.15) 4.5 % -0.46 [ -3.01, 2.09 ]
Gotoh 2005 69 -5.9 (5.82) 75 -8.4 (6.95) 6.4 % 2.50 [ 0.41, 4.59 ]
Griwan 2014 60 -9.38 (3.16) 60 -9.8 (3.65) 15.2 % 0.42 [ -0.80, 1.64 ]
Hanyu 2010 36 -6.1 (7.2) 32 -5.3 (4.9) 3.5 % -0.80 [ -3.70, 2.10 ]
Ikemoto 2003 31 8.5 (6.1) 34 9.2 (5.2) 3.9 % -0.70 [ -3.47, 2.07 ]
Ju 2002 39 -8.82 (4.5) 38 -9.21 (4.54) 6.8 % 0.39 [ -1.63, 2.41 ]
Kwon 2018 49 -3.8 (6.3) 45 -4 (7.1) 4.0 % 0.20 [ -2.52, 2.92 ]
Masumori 2009 38 -3.8 (5.1) 35 -7.2 (6.1) 4.4 % 3.40 [ 0.81, 5.99 ]
Momose 2007 20 -6.7 (6.43) 25 -7.3 (7) 2.0 % 0.60 [ -3.33, 4.53 ]
Nishino 2006 34 8.9 (3.2) 34 9.3 (3) 11.5 % -0.40 [ -1.87, 1.07 ]
Ukimura 2008 25 7.8 (5.1) 23 9.2 (6.6) 2.7 % -1.40 [ -4.76, 1.96 ]
Yokoyama 2011 42 11.3 (1.1) 39 10.7 (1.4) 35.1 % 0.60 [ 0.05, 1.15 ]
Total (95% CI) 482 483 100.0 % 0.47 [ -0.09, 1.04 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 13.23, df = 11 (P = 0.28); I2 =17%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Naftopidil versus tamsulosin, Outcome 2 International Prostate Symptom
Score-Quality of Life.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 1 Naftopidil versus tamsulosin
Outcome: 2 International Prostate Symptom Score-Quality of Life
Study or subgroup Naftopidil Tamsulosin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fujihara 2010 39 -1.01 (1.31) 43 -0.72 (3.78) 2.3 % -0.29 [ -1.49, 0.91 ]
Gotoh 2005 69 -1.3 (1.66) 75 -1.4 (1.3) 9.6 % 0.10 [ -0.39, 0.59 ]
Griwan 2014 60 -2.75 (0.56) 60 -2.75 (0.56) 19.4 % 0.0 [ -0.20, 0.20 ]
Hanyu 2010 36 -1.8 (1.16) 32 -1.4 (1.3) 7.5 % -0.40 [ -0.99, 0.19 ]
Ikemoto 2003 31 3.2 (1.83) 34 3.12 (1.92) 3.8 % 0.08 [ -0.83, 0.99 ]
Kwon 2018 49 -0.6 (1.25) 45 -0.8 (1.3) 8.9 % 0.20 [ -0.32, 0.72 ]
Masumori 2009 38 -1 (1.2) 35 -1.9 (1.8) 5.7 % 0.90 [ 0.19, 1.61 ]
Momose 2007 20 -0.6 (0.95) 25 -0.7 (1.22) 6.8 % 0.10 [ -0.53, 0.73 ]
Nishino 2006 34 2.6 (1.1) 34 2.7 (1.1) 8.8 % -0.10 [ -0.62, 0.42 ]
Ukimura 2008 16 2.5 (1.3) 22 2.8 (1.3) 4.4 % -0.30 [ -1.14, 0.54 ]
Yokoyama 2011 42 -1.45 (0.2) 39 -1.79 (0.3) 22.7 % 0.34 [ 0.23, 0.45 ]
Total (95% CI) 434 444 100.0 % 0.11 [ -0.09, 0.30 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 20.93, df = 10 (P = 0.02); I2 =52%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Naftopidil versus tamsulosin, Outcome 3 Treatment withdrawals for any reason.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 1 Naftopidil versus tamsulosin
Outcome: 3 Treatment withdrawals for any reason
Study or subgroup Naftopidil Tamsulosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Griwan 2014 0/60 0/60 Not estimable
Hanyu 2010 19/55 18/50 51.3 % 0.96 [ 0.57, 1.61 ]
Ju 2002 2/39 1/38 2.5 % 1.95 [ 0.18, 20.61 ]
Masumori 2009 10/48 12/47 25.4 % 0.82 [ 0.39, 1.70 ]
Momose 2007 0/20 0/25 Not estimable
Nishino 2006 0/17 0/17 Not estimable
Singh 2013 5/50 4/51 8.8 % 1.28 [ 0.36, 4.48 ]
Yokoyama 2011 5/46 7/45 12.0 % 0.70 [ 0.24, 2.04 ]
Total (95% CI) 335 333 100.0 % 0.92 [ 0.64, 1.34 ]
Total events: 41 (Naftopidil), 42 (Tamsulosin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 4 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Naftopidil versus tamsulosin, Outcome 4 Treatment withdrawals due to
adverse events.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 1 Naftopidil versus tamsulosin
Outcome: 4 Treatment withdrawals due to adverse events
Study or subgroup Naftopidil Tamsulosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Griwan 2014 0/60 0/60 Not estimable
Hanyu 2010 6/50 1/40 20.0 % 4.80 [ 0.60, 38.26 ]
Ikemoto 2003 3/43 2/53 28.4 % 1.85 [ 0.32, 10.57 ]
Ju 2002 1/39 1/38 11.5 % 0.97 [ 0.06, 15.02 ]
Masumori 2009 3/45 2/46 28.5 % 1.53 [ 0.27, 8.75 ]
Momose 2007 0/20 0/25 Not estimable
Nishino 2006 0/17 0/17 Not estimable
Singh 2013 0/50 0/51 Not estimable
Yokoyama 2011 1/42 1/39 11.5 % 0.93 [ 0.06, 14.34 ]
Total (95% CI) 366 369 100.0 % 1.82 [ 0.72, 4.61 ]
Total events: 14 (Naftopidil), 7 (Tamsulosin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 4 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Naftopidil versus tamsulosin, Outcome 5 Acute urinary retention.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 1 Naftopidil versus tamsulosin
Outcome: 5 Acute urinary retention
Study or subgroup Naftopidil Tamsulosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanyu 2010 0/50 0/40 Not estimable
Singh 2013 4/50 5/51 100.0 % 0.82 [ 0.23, 2.86 ]
Yokoyama 2011 0/42 0/39 Not estimable
Total (95% CI) 142 130 100.0 % 0.82 [ 0.23, 2.86 ]
Total events: 4 (Naftopidil), 5 (Tamsulosin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Naftopidil versus tamsulosin, Outcome 6 Surgical intervention.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 1 Naftopidil versus tamsulosin
Outcome: 6 Surgical intervention
Study or subgroup Naftopidil Tamsulosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanyu 2010 0/50 0/40 Not estimable
Yokoyama 2011 0/42 0/39 Not estimable
Total (95% CI) 92 79 Not estimable
Total events: 0 (Naftopidil), 0 (Tamsulosin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Naftopidil versus tamsulosin, Outcome 7 Cardiovascular adverse events.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 1 Naftopidil versus tamsulosin
Outcome: 7 Cardiovascular adverse events
Study or subgroup Naftopidil Tamsulosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gotoh 2005 7/90 1/95 8.2 % 7.39 [ 0.93, 58.87 ]
Griwan 2014 7/60 7/60 28.1 % 1.00 [ 0.37, 2.68 ]
Hanyu 2010 0/50 1/40 3.7 % 0.27 [ 0.01, 6.41 ]
Ju 2002 1/39 0/38 3.7 % 2.93 [ 0.12, 69.64 ]
Masumori 2009 3/45 2/46 11.2 % 1.53 [ 0.27, 8.75 ]
Momose 2007 0/20 1/25 3.7 % 0.41 [ 0.02, 9.62 ]
Nishino 2006 0/17 0/17 Not estimable
Singh 2013 9/50 15/51 41.3 % 0.61 [ 0.30, 1.27 ]
Yokoyama 2011 0/42 0/39 Not estimable
Total (95% CI) 413 411 100.0 % 0.97 [ 0.52, 1.80 ]
Total events: 27 (Naftopidil), 27 (Tamsulosin)
Heterogeneity: Tau2 = 0.10; Chi2 = 7.01, df = 6 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Naftopidil versus tamsulosin, Outcome 8 Sexual adverse events.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 1 Naftopidil versus tamsulosin
Outcome: 8 Sexual adverse events
Study or subgroup Naftopidil Tamsulosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanyu 2010 0/50 0/40 Not estimable
Masumori 2009 2/45 4/46 24.5 % 0.51 [ 0.10, 2.65 ]
Nishino 2006 0/17 0/17 Not estimable
Singh 2013 5/50 10/51 66.6 % 0.51 [ 0.19, 1.39 ]
Yokoyama 2011 1/42 1/39 8.9 % 0.93 [ 0.06, 14.34 ]
Total (95% CI) 204 193 100.0 % 0.54 [ 0.24, 1.22 ]
Total events: 8 (Naftopidil), 15 (Tamsulosin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Naftopidil versus silodosin, Outcome 1 International Prostate Symptom Score.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 2 Naftopidil versus silodosin
Outcome: 1 International Prostate Symptom Score
Study or subgroup Naftopidil Silodosin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Masuda 2012 34 -6.8 (4.85) 30 -8.6 (5.16) 17.3 % 1.80 [ -0.66, 4.26 ]
Matsukawa 2017 157 -6.2 (6.55) 157 -7.5 (6.55) 21.8 % 1.30 [ -0.15, 2.75 ]
Shirakawa 2013 56 -3.56 (5.87) 56 -6.02 (5.27) 19.1 % 2.46 [ 0.39, 4.53 ]
Yamaguchi 2013 38 -5.8 (6) 41 -7.4 (5.4) 17.0 % 1.60 [ -0.92, 4.12 ]
Yokoyama 2011 42 -6.1 (1.1) 41 -4.9 (1.2) 24.9 % -1.20 [ -1.70, -0.70 ]
Total (95% CI) 327 325 100.0 % 1.04 [ -0.78, 2.85 ]
Heterogeneity: Tau2 = 3.38; Chi2 = 27.22, df = 4 (P = 0.00002); I2 =85%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours naftopidil Favours silodosin
105Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Naftopidil versus silodosin, Outcome 2 International Prostate Symptom Score-
Quality of Life.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 2 Naftopidil versus silodosin
Outcome: 2 International Prostate Symptom Score-Quality of Life
Study or subgroup Naftopidil Silodosin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Masuda 2012 34 -1.3 (1.24) 30 -2 (1.2) 16.9 % 0.70 [ 0.10, 1.30 ]
Matsukawa 2017 157 -1.6 (0.94) 157 -1.9 (0.94) 23.1 % 0.30 [ 0.09, 0.51 ]
Shirakawa 2013 56 -0.95 (1.27) 56 -0.98 (1.26) 19.1 % 0.03 [ -0.44, 0.50 ]
Yamaguchi 2013 38 -1 (1.4) 41 -1.6 (1.3) 16.9 % 0.60 [ 0.00, 1.20 ]
Yokoyama 2011 42 -1.45 (0.2) 41 -1.1 (0.2) 24.1 % -0.35 [ -0.44, -0.26 ]
Total (95% CI) 327 325 100.0 % 0.21 [ -0.23, 0.66 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 50.20, df = 4 (P<0.00001); I2 =92%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Naftopidil versus silodosin, Outcome 3 Treatment withdrawals for any reason.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 2 Naftopidil versus silodosin
Outcome: 3 Treatment withdrawals for any reason
Study or subgroup Naftopidil Silodosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Matsukawa 2017 18/175 18/175 48.3 % 1.00 [ 0.54, 1.86 ]
Shirakawa 2013 4/60 5/61 11.5 % 0.81 [ 0.23, 2.88 ]
Yamaguchi 2013 6/44 12/53 23.1 % 0.60 [ 0.25, 1.47 ]
Yokoyama 2011 5/46 8/45 17.1 % 0.61 [ 0.22, 1.73 ]
Total (95% CI) 325 334 100.0 % 0.80 [ 0.52, 1.23 ]
Total events: 33 (Naftopidil), 43 (Silodosin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Naftopidil versus silodosin, Outcome 4 Treatment withdrawals due to adverse
events.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 2 Naftopidil versus silodosin
Outcome: 4 Treatment withdrawals due to adverse events
Study or subgroup Naftopidil Silodosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Masuda 2012 2/48 1/44 9.7 % 1.83 [ 0.17, 19.52 ]
Matsukawa 2017 8/175 7/175 55.3 % 1.14 [ 0.42, 3.08 ]
Shirakawa 2013 1/57 3/59 10.9 % 0.35 [ 0.04, 3.22 ]
Yamaguchi 2013 1/44 5/53 12.2 % 0.24 [ 0.03, 1.99 ]
Yokoyama 2011 1/42 4/41 11.8 % 0.24 [ 0.03, 2.09 ]
Total (95% CI) 366 372 100.0 % 0.72 [ 0.35, 1.51 ]
Total events: 13 (Naftopidil), 20 (Silodosin)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.91, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Naftopidil versus silodosin, Outcome 5 Acute urinary retention.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 2 Naftopidil versus silodosin
Outcome: 5 Acute urinary retention
Study or subgroup Naftopidil Silodosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yamaguchi 2013 0/44 0/53 Not estimable
Yokoyama 2011 0/42 0/41 Not estimable
Total (95% CI) 86 94 Not estimable
Total events: 0 (Naftopidil), 0 (Silodosin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours naftopidil Favours silodosin
Analysis 2.6. Comparison 2 Naftopidil versus silodosin, Outcome 6 Surgical intervention.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 2 Naftopidil versus silodosin
Outcome: 6 Surgical intervention
Study or subgroup Naftopidil Silodosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yamaguchi 2013 0/44 0/53 Not estimable
Yokoyama 2011 0/42 0/41 Not estimable
Total (95% CI) 86 94 Not estimable
Total events: 0 (Naftopidil), 0 (Silodosin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours naftopidil Favours silodosin
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Analysis 2.7. Comparison 2 Naftopidil versus silodosin, Outcome 7 Cardiovascular adverse events.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 2 Naftopidil versus silodosin
Outcome: 7 Cardiovascular adverse events
Study or subgroup Naftopidil Silodosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Masuda 2012 3/79 3/83 34.0 % 1.05 [ 0.22, 5.05 ]
Matsukawa 2017 4/175 2/175 29.6 % 2.00 [ 0.37, 10.78 ]
Shirakawa 2013 1/57 1/59 11.1 % 1.04 [ 0.07, 16.16 ]
Yamaguchi 2013 1/44 3/53 16.9 % 0.40 [ 0.04, 3.73 ]
Yokoyama 2011 0/42 1/41 8.3 % 0.33 [ 0.01, 7.77 ]
Total (95% CI) 397 411 100.0 % 0.98 [ 0.39, 2.44 ]
Total events: 9 (Naftopidil), 10 (Silodosin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.78, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours naftopidil Favours silodosin
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Analysis 2.8. Comparison 2 Naftopidil versus silodosin, Outcome 8 Sexual adverse events.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 2 Naftopidil versus silodosin
Outcome: 8 Sexual adverse events
Study or subgroup Naftopidil Silodosin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Masuda 2012 0/79 5/83 12.0 % 0.10 [ 0.01, 1.70 ]
Shirakawa 2013 0/57 1/59 9.8 % 0.34 [ 0.01, 8.29 ]
Yamaguchi 2013 2/21 10/23 50.8 % 0.22 [ 0.05, 0.89 ]
Yokoyama 2011 1/15 10/11 27.4 % 0.07 [ 0.01, 0.49 ]
Total (95% CI) 172 176 100.0 % 0.15 [ 0.06, 0.42 ]
Total events: 3 (Naftopidil), 26 (Silodosin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.21, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.69 (P = 0.00023)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours naftopidil Favours silodosin
Analysis 3.1. Comparison 3 Naftopidil versus propiverine, Outcome 1 International Prostate Symptom
Score.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 3 Naftopidil versus propiverine
Outcome: 1 International Prostate Symptom Score
Study or subgroup Naftopidil Propiverine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yokoyama 2009 19 -4.9 (5.85) 18 -2.1 (7.05) -2.80 [ -6.99, 1.39 ]
-10 -5 0 5 10
Favours naftopidil Favours propiverine
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Analysis 3.2. Comparison 3 Naftopidil versus propiverine, Outcome 2 International Prostate Symptom
Score-Quality of Life.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 3 Naftopidil versus propiverine
Outcome: 2 International Prostate Symptom Score-Quality of Life
Study or subgroup Naftopidil Propiverine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yokoyama 2009 19 -0.9 (1.02) 18 -1 (1.02) 0.10 [ -0.56, 0.76 ]
-2 -1 0 1 2
Favours naftopidil Favours propiverine
Analysis 4.1. Comparison 4 Naftopidil versus Eviprostat, Outcome 1 International Prostate Symptom
Score.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 4 Naftopidil versus Eviprostat
Outcome: 1 International Prostate Symptom Score
Study or subgroup Naftopidil Eviprostat
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yamanishi 2004 36 -5.9 (4.3) 13 0.4 (5.2) -6.30 [ -9.46, -3.14 ]
-10 -5 0 5 10
Favours naftopidil Favours Eviprostat
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Analysis 4.2. Comparison 4 Naftopidil versus Eviprostat, Outcome 2 International Prostate Symptom
Score-Quality of Life.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 4 Naftopidil versus Eviprostat
Outcome: 2 International Prostate Symptom Score-Quality of Life
Study or subgroup Naftopidil Eviprostat
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yamanishi 2004 36 -1.5 (1.5) 13 0 (1.3) -1.50 [ -2.36, -0.64 ]
-2 -1 0 1 2
Favours naftopidil Favours Eviprostat
Analysis 4.3. Comparison 4 Naftopidil versus Eviprostat, Outcome 3 Treatment withdrawals for any reason.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 4 Naftopidil versus Eviprostat
Outcome: 3 Treatment withdrawals for any reason
Study or subgroup Naftopidil Eviprostat Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yamanishi 2004 0/36 0/13 Not estimable
0.5 0.7 1 1.5 2
Favours naftopidil Favours Eviprostat
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Analysis 4.4. Comparison 4 Naftopidil versus Eviprostat, Outcome 4 Treatment withdrawals due to adverse
events.
Review: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Comparison: 4 Naftopidil versus Eviprostat
Outcome: 4 Treatment withdrawals due to adverse events
Study or subgroup Naftopidil Eviprostat Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yamanishi 2004 0/36 0/13 Not estimable
0.01 0.1 1 10 100
Favours naftopidil Favours Eviprostat
A D D I T I O N A L T A B L E S
Table 1. Baseline characteristics of included studies
Study
name
Trial pe-
riod (year
to year)
Country Setting Descrip-
tion
of partici-
pants
Interven-
tion(s)
and com-
parator(s)
Dura-
tion of in-
tervention
(dura-
tion of fol-
low-up)
Mean
age (± SD;
years)
Mean
prostate
volume (±
SD; mL)
IPSS (±
SD)
Fujihara
2010
NR Japan Multicen-
tre
Men
with LUTS
with OAB
symptoms
Naftopidil
50-75 mg
once daily
12 weeks NR NR 17.61 ± 5.8
(estimated
from the
figure)
Tam-
sulosin 0.
2 mg once
daily
NR NR 15.72
± 6.96 (es-
timated
from the
figure)
Gotoh
2005
NR Japan Multicen-
tre (16 in-
vestiga-
tional sites)
Men
aged ≥ 50
years, IPSS
≥ 8, Qmax
< 15 mL/s
(voided
volume ≥
Naftopidil
25 mg/day
for 2
weeks, fol-
lowed
by 50 mg/
day for 10
12 weeks 68.0 ± 7.2
(calculated
from 95%
CI 66.4 to
69.8)
29.0 ± 10.2
(calculated
from 95%
CI 27.2 to
32.0)
15.5 ± 5.7
(calculated
from 95%
CI 14.1 to
16.8)
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Table 1. Baseline characteristics of included studies (Continued)
150 mL),
prostate ≥
20 mL
weeks
Tam-
sulosin 0.2
mg/day for
12 weeks
68.5 ± 6.8
(calculated
from 95%
CI 67.0 to
70.1)
33.6 ± 18.1
(calculated
from 95%
CI 29.5 to
37.7)
17.1 ± 6.18
(calculated
from 95%
CI 15.7 to
18.5)
Griwan
2014
NR India Single in-
stitution
Men aged
≥ 45 years,
daytime
frequency
> 8, noc-
turnal fre-
quency > 2,
Qmax 5-15
mL/s (150
mL voided
volume),
PVR < 150
mL, IPSS
> 13, IPSS
bother
score > 3
Naftopidil
75 mg/day
3 months NR 56.81 ± 6.
45
21.31 ± 4.
04
Tam-
sulosin 0.4
mg/day
NR 57.73 ± 7.
33
21.95 ± 4.
46
Hanyu
2010
2005-
2008
Japan Multicen-
tre (4 cen-
tres)
Men aged
≥ 50 years
at first visit,
to-
tal IPSS ≥
8, QoL in-
dex score≥
2 prostate
vol-
ume ≥ 20
mL, PVR <
100 mL
Naftopidil
50 mg/day
12 weeks 70.5 ± 5.8 40.2 ± 16.3 14.8 ± 5.7
Tam-
sulosin 0.2
mg/day
70.9 ± 5.8 41.0 ± 19.3 13.5 ± 5.0
Ikemoto
2003
2000-
2002
Japan 3
hospitals in
single insti-
tute
IPSS ≥ 8;
Qmax < 12
mL/
s (150 mL
voiding)
;, if prior
BPH med-
ication, 1
month
Naftopidil
25 mg/day
for first 2
weeks,
then 50 mg
once daily
for 6 weeks
then tam-
sulosin 0.2
8
weeks (ad-
ditional 8
weeks after
cross-over/
no
washout)
66.6 ± 7.6 38.9 ± 11.8 17.4 ± 6.0
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Table 1. Baseline characteristics of included studies (Continued)
washout
period
mg for 8
weeks
Tam-
sulosin 0.2
mg for 8
weeks then
naftopidil
25mg for 2
weeks,
then 50 mg
for 6 weeks
63.8 ± 9.1 32.7 ± 9.4 16.8 ± 7.2
Ju 2002 2011 China Single in-
stitution
Men aged
50-75 years
with BPH,
IPSS ≥ 13,
PSA ≤ 4
ng/mL,
Qmax 5-15
mL/s when
urine vol-
ume > 150
mL
Nafto-
pidil 25mg
once daily
6 weeks 62.5 ± 5.26 NR 18.79 ± 4.8
Tam-
sulosin 0.
2 mg once
daily
66.5 ± 5.8 NR 19.71 ± 4.7
Kwon
2018
2015 Korea Multicen-
tre
94 men
who had
been tak-
ing tamsu-
losin for
more than
8 weeks;
however,
men who
persisted
> 3 points
of OABSS,
especially >
2 points of
OABSS
question 3
Naftopidil
75 mg/day
for 8 weeks
8 weeks 66.0 ± 6.3 36.8 ± 14.6 16.9 ± 6.2
Tam-
sulosin 0.
2 mg once
daily for 8
weeks
64.8 ± 7.7 37.5 ± 22.4 19.1 ± 7.2
Li 2007 2002-
2003
China Multicen-
tre (9 cen-
tres)
Men
with BPH/
LUTS
aged 50-75
years, total
IPSS ≥ 13,
prostate
Nafto-
pidil 25mg
once daily
12 month 67.7 ± 5.5 38.1 ± 15.4 20.6 ± 5.4
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Table 1. Baseline characteristics of included studies (Continued)
vol-
ume > 20
mL, Qmax
< 15 mL/s,
PVR < 60
mL
Tam-
sulosin 0.
2 mg once
daily
66.8 ± 5.4 43.1 ± 17.7 21.1 ± 5.6
Masuda
2012
2009-
2011
Japan Multicen-
tre
Men with
LUTS/
BPH,
prostate
volume
≥ 20 cm3,
IPSS ≥ 8,
QoL score
≥ 3, clini-
cal diagno-
sis of BPH,
aged ≥ 50
years, no
prior treat-
ment for
BPH
Nafto-
pidil 50-75
mg once/
daily for 2
weeks,
then 75 mg
once daily
for 4 weeks
6
weeks (ad-
ditional 6
weeks after
cross-over,
no
washout)
68.5 ± 5.7 45.7 ± 17.8 17.6 ± 5.0
Silodosin
2-
4 mg twice
daily for 2
weeks,
then 4 mg
twice daily
for 4 weeks
66.5 ± 5.6 38.8 ± 13.1 18.6 ± 5.5
Masumori
2009
2005-
2006
Japan Multicen-
tre (17 cen-
tres)
Men with
LUTS/
BPH,
aged 51-79
years, IPSS
≥ 8
Nafto-
pidil 50mg
once daily
12 weeks 64.5 ± 7.7 35.9 ± 15.3 15.0 ± 5.9
Tam-
sulosin 0.
2 mg once
daily
65.2 ± 7.5 34.4 ± 13.7 17.8 ± 5.7
Mat-
sukawa
2017
2012-
2013
Japan Multicen-
tre
Men aged
≥ 50 years,
total IPSS
≥ 8, IPSS-
QoL score
≥ 3, to-
tal OABSS
≥ 3, ≥ 1
urinary ur-
gency
episodes/
Naftopidil
50 mg/day
for 4
weeks, fol-
lowed by
75 mg/day
for 8 weeks
12 weeks 70.3 ± 7.8 38.6 ± 14.8 18.9 ± 6.1
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Table 1. Baseline characteristics of included studies (Continued)
week,
prostate
volume
≥ 20 mL
on transab-
dom-
inal ultra-
sonogra-
phy, Qmax
< 15 mL/s
at a voided
volume of
≥ 100 mL
and PVR <
150 mL
Silodosin 4
mg/day for
4
weeks, fol-
lowed by 8
mg/day for
8 weeks
70.6 ± 7.8 39.6 ± 16.7 18.8 ± 6.2
Momose
2007
2002-
2003
Japan Single cen-
tre
Men with
LUTS with
BPH
Naftopidil
50 mg/day
for 4 weeks
then tam-
sulosin 0.2
mg/day for
4 weeks
28 days
(additional
28 days af-
ter cross-
over, no
washout)
65.3 ± 5.5 30.7 ± 13.8 19.6 ± 7.0
Tamsu-
losin
0.2 mg/day
for 4 weeks
and nafto-
pidil
50 mg/day
4 weeks
68.2 ± 7.7 47.2 ± 22.6 18.4 ± 6.9
Nishino
2006
NR Japan Single cen-
tre
Men with
LUTS sec-
ondary to
BPH
Naftopidil
50 mg/day
for 4 weeks
then tam-
sulosin 0.2
mg for 4
weeks
4
weeks: data
analysis (4
weeks be-
fore cross-
over. 1-
week
washout,
and ad-
ditional 4
weeks after
cross-over)
73.2 ± 4.1 20.6 ± 3.7 20.7 ± 4.3
Tamsu-
losin
71.5 ± 4.5 18.9 ± 2.8 20.1 ± 2.7
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Table 1. Baseline characteristics of included studies (Continued)
0.2 mg/day
for 4 weeks
then nafto-
pidil 50mg
for 4 weeks
Perumal
2015
2011-
2013
India Single cen-
tre
Men aged>
50
years, clin-
ical symp-
toms of
BPE,
LUTS,
with
or without
raised PVR
urine
Nafto-
pidil 50mg
once daily
30 days 59.9 ± 5.5 NR 19.97 ± 2.
53
Tam-
sulosin 0.
4 mg once
daily
60.1 ± 5.0 NR 21.3 ± 2.84
Shirakawa
2013
2007-
2011
Japan Kobe Uni-
versity
School or
other col-
laborat-
ing institu-
tions
Men with
BPH/
LUTS,
total IPSS
8 points,
QoL index
3 points,
Qmax <
15 mL/s,
prostate
volume
20 mL;
either men
without
history
of using
any a1-
receptor
blocker
(hereafter,
drug-naive
group)
or men
who had
continued
to use
tamsulosin
0.2 mg
once daily
for ≥ 3
Nafto-
pidil 50mg
once daily
8 consecu-
tive weeks
70.50 ± 6.
58
39.39 ± 25.
96
17.56 ± 6.
73
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Table 1. Baseline characteristics of included studies (Continued)
months
and
wanted to
switch the
medication
to another
oral drug
(hereafter,
drug-
switching
group)
Silodosin 4
mg twice
daily
70.98 ± 6.
69
38.24 ± 12.
94
17.53 ± 5.4
Singh
2013
2010-
2012
India Single in-
stitution
Men with
BPH; IPSS
> 8 or >
3 points for
frequency,
noc-
turia, and
urgency on
IPSS;
prostate
volume
>15mL, or
peak
flow rate <
10 mL for
voided vol-
ume > 150
mL
Nafto-
pidil 50mg
once daily
12 weeks 61.69 31.38 21.06
Tam-
sulosin 0.
4 mg once
daily
61.15 30.01 21.53
Ub 2016 2009-
2013
Japan Multicen-
tre
Men with
OAB and
BPH, who
met the fol-
lowing
criteria and
were not
adminis-
tered med-
ication (ex-
cept herbal
prepara-
tion)
for urinary
dis-
order: IPSS
≥ 2, QoL
Naftopidil
75 mg/day
8
weeks (ad-
ditional 8
weeks after
cross-over,
no
washout:
authors
judged that
evaluation
without
washout
pe-
riod would
be feasible)
74.7 ± 8.0 NR 17.4 ± 6.7
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Table 1. Baseline characteristics of included studies (Continued)
score ≥ 2,
OABSS ≥
3 (urgency
score ≥ 2)
Tam-
sulosin 0.2
mg/
day + so-
lifenacin 5
mg/day
71.9 ± 8.3 NR 18.1 ± 5.4
Ukimura
2008
2004-
2007
Japan Multicen-
tre
Men aged
≥ 50 years,
number of
nocturia ≥
2, IPSS ≥
8, QoL in-
dex ≥
3, residual
urine vol-
ume < 50
mL (evalu-
ated by ul-
trasound
estima-
tion), max-
imum
voiding
flow rate <
15 mL/s
(preferably
with a uri-
nation vol-
ume
≥ 150 mL)
, prostate
volume <
50 mL
Nafto-
pidil 50mg
once daily
6-8 weeks 69.6 ± 6.8 24.4 ± 6.9 17.2 ± 6.4
Tam-
sulosin 0.
2 mg once
daily
68.8 ± 8.2 26.7 ± 7.9 18.9 ± 6.6
Yamaguchi
2013
2007-
2010
Japan Multicen-
tre
Men with
BPH aged
≥ 50 years,
signifi-
cant LUTS
and deteri-
orated
QoL, IPSS
≥ 8, IPSS-
QoL score
Naftopidil
75 mg/day
12 weeks 70.0 ± 7.0 39.5 ± 18.0 18.9 ± 7.0
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Table 1. Baseline characteristics of included studies (Continued)
≥ 3
Silodosin 8
mg/day
69.3 ± 7.8 33.2 ± 21.2 16.9 ± 5.5
Yamanishi
2004
NR Japan Single cen-
tre
IPSS ≥ 8,
Qmax < 12
mL/
s, prostate
volume ≥
15 mL, ob-
structive
(or equivo-
cal) condi-
tion on In-
ternational
Conti-
nence Soci-
ety nomo-
gram as as-
sessed in a
pressure/
flow study
Naftopidil
25mg once
daily for 2
weeks,
then 50 mg
once
daily for 2
weeks,
then 75 mg
once daily
for 2 weeks
6 weeks 67.5 ± 8.2 29.7 ± 14.9 15.4 ± 5.7
Eviprostat
6 tablets
daily
69.0 ± 6.5 29.5 ± 15.9 16.0 ± 6.9
Yokoyama
2009
2004-
2007
Japan 2 centres Men aged
≥ 50 years,
IPSS ≥
8, 2-day
frequency
volume
chart
showing ≥
1 episode/
day of
urinary
urgency,
daytime
voiding
frequency
≥ 8
episodes/
day, night-
time void-
ing fre-
quency ≥
1 episode/
night, PVR
Naftopidil
50 mg/day
4 weeks 69.1 ± 8.3 26.6 ± 12.3 18.2 ± 5.7
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Table 1. Baseline characteristics of included studies (Continued)
≤ 50 mL.
Men with
elevated
serum PSA
level (>
10 ng/
mL) were
confirmed
as having
BPH
before the
treatment
by tran-
srectal ul-
trasound-
guided
prostate
sextant
biopsies
Propiver-
ine
hydrochlo-
ride 20mg/
day
70.9 ± 6.7 25.3 ± 7.7 18.2 ± 7.0
Yokoyama
2011
NR Japan 2 centres Men
with LUTS
aged 50-80
years, IPSS
≥ 8
Nafto-
pidil 50mg
once daily
12 weeks 69.1 ± 1.2 35.0 ± 3.1 17.4 ± 0.8
Tam-
sulosin 0.
2 mg once
daily
71.5 ± 1.1 32.5 ± 2.0 18.0 ± 1.1
Silodosin 4
mg twice
daily
70.2 ± 0.9 33.3 ± 2.3 18.7 ± 0.7
BPE: benign prostatic enlargement; BPH: benign prostatic hyperplasia; CI: confidence interval; IPSS: International Prostate Symptom
Score; LUTS: lower urinary tract symptoms; NR: not reported; OAB: overactive bladder; OABSS: overactive bladder symptom score;
PSA: prostate-specific antigen; PVR: postvoid residual; Qmax : maximum flow rate; QoL: quality of life; s: second; SD: standard
deviation.
Table 2. Participants in included studies
Study name Intervention(s) and
comparator(s)
Screened/eligible
(n)
Randomised (n) Analysed (n) Finishing trial (n (%))
Fujihara 2010 Naftopidil 50-75mg
once daily
NR/82 39 NR NR
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Table 2. Participants in included studies (Continued)
Tamsulosin 0.2 mg
once daily
43 NR NR
Total 82 NR NR
Gotoh 2005 Naftopidil 25 mg/
day for 2 weeks, fol-
lowed by 50 mg/day
for 10 weeks
185/144 69 69 69
Tamsulosin 0.2 mg/
day
75 75 75
Total 144 144 144 (100)
Griwan 2014 Naftopidil 75 mg/
day
NR/120 60 60 60
Tamsulosin 0.4 mg/
day
60 60 60
Total 120 120 120 (100)
Hanyu 2010 Naftopidil 50 mg/
day
NR/105 55 36 36
Tamsulosin 0.2 mg/
day
50 32 32
Total 105 68 68 (64.8)
Ikemoto 2003 Naftopidil 25 mg/
day for first 2 weeks,
then 50 mg once
daily for 6 weeks
then tamsulosin 0.2
mg for 8 weeks
NR/96 43 31 31
Tamsulosin 0.2 mg
for 8 weeks then
naftopidil 25 mg for
2 weeks, then 50 mg
for 6 weeks
53 34 34
Total 96 65 65 (67.7)
Ju 2002 Naftopidil 25 mg
once daily
80/80 40 39 39
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Table 2. Participants in included studies (Continued)
Tamsulosin 0.2 mg
once daily
40 38 38
Total 80 77 77 (96.3)
Kwon 2018 Naftopidil 75 mg/
day
NR/94 49 NR NR
Tamsulosin 0.2 mg
once daily
45 NR NR
Total 94 - -
Li 2007 Naftopidil 25 mg
once daily
906/906 126 NR NR
Tamsulosin 0.2 mg
once daily
138 NR NR
Total 264 - -
Masuda 2012 Naftopidil 50-75mg
once for 2 weeks,
then 75 mg once
daily for 4 weeks
NR/92 48 34 34
Silodosin 2-4 mg
twice daily for 2
weeks, then 4 mg
twice daily for 4
weeks
44 30 30
Total 92 64 64 (69.6)
Masumori 2009 Naftopidil 50 mg/
day
NR/95 48 38 38
Tamsulosin 0.2 mg/
day
47 35 35
Total 95 73 73 (76.8)
Matsukawa 2017 Naftopidil 50mg for
4 weeks, then 75 mg
for 8 weeks
NR/350 175 157 157
Silodosin 4 mg for 4
weeks, then 8 mg for
8 weeks
175 157 157
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Table 2. Participants in included studies (Continued)
Total 350 314 314 (89.7)
Momose 2007 Naftopidil 50 mg/ 4
weeks, then tamsu-
losin 0.2 mg/day for
4 weeks
NR/45 20 20 20
Tamsulosin 0.2 mg
for 4 weeks, then
naftopidil 50 mg/
day for 4 weeks
25 25 25
Total 45 45 45 (100)
Nishino 2006 Naftopidil 50 mg/
day 4 weeks, then
tamsulosin 0.2 mg/
day 4 weeks
NR/34 17 17 17
Tamsulosin 0.2 mg/
day 4 weeks, then
naftopidil 50 mg/
day 4 weeks
17 17 17
Total 34 34 34 (100)
Perumal 2015 Naftopidil 50 mg
once daily
NR/60 30 NR NR
Tamsulosin 0.4 mg
once daily
30 NR NR
Total 60 NR NR
Shirakawa 2013 Naftopidil 50 mg
once daily
NR/121 60 56/57 56
Silodosin 4mg twice
daily
61 56/59 56
Total 121 112/116 112 (92.5)
Singh 2013 Naftopidil 50 mg
once daily
NR/110 55 50 50
Tamsulosin 0.4 mg
once daily
55 51 51
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Table 2. Participants in included studies (Continued)
Total 110 101 101 (91.8)
Ub 2016 Naftopidil 75 mg/
day
NR/59 NR 14 14
Tamsulosin 0.2 mg/
day + solifenacin 5
mg/day
NR 17 17
Total NR 31 31
Ukimura 2008 Naftopidil 50 mg
once daily
NR/81 NR 31 31
Tamsulosin 0.2 mg
once daily
NR 28 28
Total NR 59 59
Yamaguchi 2013 Naftopidil 75 mg/
day
109/109 51 44 44
Silodosin 8 mg/day 58 53 53
Total 109 97 97 (90.0)
Yamanishi 2004 Naftopidil 25 mg
once daily for 2
weeks, then 50 mg
once daily for 2
weeks, and then 75
mg once daily for 2
weeks
NR/49 36 36 36
Eviprostat 6 tablets
daily
13 13 13
Total 49 49 49 (100)
Yokoyama 2009 Naftopidil 50 mg/
day
NR/58 19 19 19
Propiver-
ine hydrochloride 20
mg/day
18 18 18
Total 37 37 37 (100)
127Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Participants in included studies (Continued)
Yokoyama 2011 Naftopidil 50 mg
once daily
136/136 46 42 42
Tamsulosin 0.2 mg
once daily
45 39 39
Silodosin 4mg twice
daily
45 41 41
Total 136 122 122 (89.7)
Overall total Interventions:
naftopidil
Ub 2016; Ukimura
2008 did not report
1086a - 793b
Comparator: tamsu-
losin
Ub 2016; Ukimura
2008 did not report
723a - 451b
Comparator:
silodosin
- 383 - 337 (87.9)
Comparator:
propiverine
- 18 - 18 (100)
Comparator:
Eviprostat
- 13 - 13 (100)
Overall - 2223 - 1612 (72.5)
n: number; NR: not reported.
aTwo included studies did not report the number of randomised participants (Ub 2016; Ukimura 2008).
bFour included studies did not report the number of participants who finished trials (Fujihara 2010; Kwon 2018; Li 2007; Perumal
2015).
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A P P E N D I C E S
Appendix 1. Search strategies
The Cochrane Library (via Wiley) search strategy
1 ’MeSH descriptor: [Prostatic Hyperplasia] explode all trees
2 (prostat* near/3 hyperplasia*):ti,ab,kw (Word variations have been searched)
3 (prostat* near/3 hypertroph*):ti,ab,kw (Word variations have been searched)
4 (prostat* near/3 adenoma*):ti,ab,kw (Word variations have been searched)
5 (BPH or BPO or BPE):ti,ab,kw (Word variations have been searched)
6 (prostat* near/3 (enlarg* or obstruct*)):ti,ab,kw (Word variations have been
searched)
7 MeSH descriptor: [Prostatism] explode all trees
8 prostatism:ti,ab,kw (Word variations have been searched)
9 MeSH descriptor: [Urinary Bladder Neck Obstruction] explode all trees
10 ((bladder* near/3 obstruct*) or BOO):ti,ab,kw (Word variations have been
searched)
11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
12 ’(Naftopidil or BM-15275 or KT-611 or R9PHW59SFN):ti,ab,kw (Word vari-
ations have been searched)
13 #11 and #12
MEDLINE (via PubMed) search strategy
1 exp Prostatic Hyperplasia/
2 (Prostat* adj3 hyperplasia*).tw.
3 (Prostat* adj3 hypertroph*).tw.
4 (Prostat* adj3 adenoma*).tw.
5 (BPH or BPO or BPE).tw.
6 (prostat* adj3 (enlarg* or obstruct*)).tw.
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(Continued)
7 exp Prostatism/
8 Prostatism.tw.
9 exp Urinary Bladder Neck Obstruction/
10 (Bladder* adj3 obstruct*).tw.
11 BOO.tw.
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13 ’(Naftopidil or BM-15275 or KT-611 or R9PHW59SFN).nm,tw.
14 ’(Flivas or Nafodil or Naftomax or Dishuang or Ge Rui Jia or Jun Lie Xin or Kun
Da or Lai Luo Er or Na Tuo or Pu Chang or Shu Er or Sitandi or Yu Chang or
Zai Chang).nm,tw
15 ’57149-07-2.rn.
16 13 or 14 or 15
17 12 and 15
18 randomized controlled trial.pt.
19 controlled clinical trial.pt.
20 randomized.ab.
21 placebo.ab.
22 drug therapy.fs.
23 randomly.ab.
24 trial.ab.
25 groups.ab.
26 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
27 exp animals/ not humans.sh.
28 27 not 28
29 18 and 29
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(Continued)
Embase (via Elsevier) search strategy
1 ”prostate hypertrophy’/exp
2 (Prostat* NEAR/3 hyperplasia*):ab,ti
3 (Prostat* NEAR/3 hypertroph*):ab,ti
4 (Prostat* NEAR/3 adenoma*):ab,ti
5 ”bph’:ab,ti OR ’bpo’:ab,ti OR ’bpe’:ab,ti
6 (prostat* NEAR/3 (enlarg* or obstruct*)):ab,ti
7 ”prostatism’/exp
8 ”prostatism’:ab,ti
9 ”bladder obstruction’/exp
10 (bladder* NEAR/3 obstruct*):ab,ti
11 ”BOO’:ab,ti
12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #
11
13 ”naftopidil’/exp
14 ’(Naftopidil or BM-15275 or KT-611 or R9PHW59SFN):ab,ti,tn
15 ’(Flivas or Nafodil or Naftomax or Dishuang or ’Ge Rui Jia’ or ’Jun Lie Xin’ or
’Kun Da’ or ’Lai Luo Er’ or ’Na Tuo’ or ’Pu Chang’ or ’Shu Er’ or ’Sitandi’ or
’Yu Chang’ or ’Zai Chang’):ab,ti,tn
16 ”57149-07-2’:rn
17 #13 OR #14 OR #15 OR #16
18 #12 AND #17
19 ”crossover procedure’:de OR ’double-blind procedure’:de OR ’randomized con-
trolled trial’:de OR ’single-blind procedure’:de OR random*:de,ab,ti OR fac-
torial*:de,ab,ti OR crossover*:de,ab,ti OR ((cross NEXT/1 over*):de,ab,ti) OR
placebo*:de,ab,ti OR ((doubl* NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1
blind*):de,ab,ti) OR assign*:de,ab,ti OR allocat*:de,ab,ti OR volunteer*:de,ab,
ti
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(Continued)
20 ’animals’/exp NOT (’humans’/exp AND ’animals’/exp)
21 #19 NOT #20
22 #18 AND #21
Scopus search strategy
1 TITLE-ABS-KEY((hyperplasia* W/3 prostat*) OR (hypertroph* W/3 prostat*)
OR (adenoma* W/3 prostat*) OR (prostat* W/3 (enlarg* OR obstruct*)) OR
(bph OR bpo OR bpe OR boo) OR prostatism OR (bladder* W/3 obstruct*))
2 TITLE-ABS-KEY(Naftopidil or BM-15275 or KT-611 or R9PHW59SFN or
Flivas or Nafodil or Naftomax or Dishuang or “Ge Rui Jia” or “Jun Lie Xin” or
“Kun Da” or “Lai Luo Er” or “Na Tuo” or “Pu Chang” or “Shu Er” or “Sitandi”
or “Yu Chang” or “Zai Chang”)
3 CASREGNUMBER ( 57149-07-2 )
4 CHEMNAME ( naftopidil OR bm-15275 OR kt-611 OR r9phw59sfn OR
flivas OR nafodil OR naftomax OR dishuang OR “Ge Rui Jia” OR “Jun Lie
Xin” OR “Kun Da” OR “Lai Luo Er” OR “Na Tuo” OR “Pu Chang” OR “Shu
Er” OR “Sitandi” OR “Yu Chang” OR “Zai Chang” )
5 #2 OR #3 OR #4
6 #1 AND #5
Web of Science search strategy
1 TS= ((hyperplasia* NEAR/3 prostat*) OR (hypertroph* NEAR/3 prostat*) OR
(adenoma* NEAR/3 prostat*) OR (prostat* NEAR/3 (enlarg* OR obstruct*)
) OR (bph OR bpo OR bpe OR boo) OR prostatism OR (bladder* NEAR/3
obstruct*))
2 TS= (Naftopidil or BM-15275orKT-611orR9PHW59SFNorFlivas orNafodil
or Naftomax or Dishuang or “Ge Rui Jia” or “Jun Lie Xin” or “Kun Da” or “Lai
Luo Er” or “Na Tuo” or “Pu Chang” or “Shu Er” or “Sitandi” or “Yu Chang” or
“Zai Chang”)
3 1 AND 2
LILAC search strategy
1 (mh:(“Prostatic Hyperplasia” OR prostatism OR “Urinary Bladder Neck Ob-
struction”)) OR (tw:(“Prostatic Hyperplasia” OR “Prostatic Adenoma” OR “Pro-
static Hypertrophy” OR “Prostatic Enlargement” OR bph OR bpo OR bpe OR
prostatism OR “Bladder Neck Obstruction” OR “Bladder Outlet Obstruction”
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(Continued)
OR boo)) AND (tw:(naftopidil OR bm-15275 OR kt-611 OR r9phw59sfn OR
flivas ORnafodil OR naftomax OR dishuang OR “Ge Rui Jia” OR “Jun Lie Xin”
OR “Kun Da” OR “Lai Luo Er” OR “Na Tuo” OR “Pu Chang” OR “Shu Er”
OR “Sitandi” OR “Yu Chang” OR “Zai Chang”)) AND (instance:“regional”)
World Health Organization International Clinical Trials Registry Platform Search Portal
1 prostat* AND naftopidil
ClinicalTrials.gov
1 Prostate
2 Naftopidil
3 1 AND 2
Grey literature (Open Grey)
1 prostat* AND naftopidil
Appendix 2. Survey of trial investigators providing information on included and excluded trials
Study Date trial author contacted (first) Date trial author provided data
(latest)
Data trial author provided
(short summary)
Kwon 2018 23 October 2017 23 October 2017 All data provided
Yamaguchi 1992 29 May 2018 4 June 2018 We requested full data set; however,
we received author’s reply as follows;
“I have no way to access information
on these old studies.”
Yamaguchi 1997 29 May 2018 4 June 2018 We requested full data set; however,
we received author’s reply as follows;
“I have no way to access information
on these old studies.”
Yamaguchi 2013 17 January 2017 30 January 2017 All data provided
Yokoyama 2011 30 January 2017 13 March 2017 Dates when study was conducted,
study duration (intervention), ex-
clusion criteria, conflicts of inter-
est, mean and standard deviation of
IPSS and QoL at baseline and end-
133Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
point (12 weeks), the number of
participants with acute urinary re-
tention, and surgical intervention.
Method of random sequence gener-
ation and blinding
IPSS: International Prostate Symptom Score; QoL: quality of life.
WH A T ’ S N E W
Last assessed as up-to-date: 15 June 2009.
Date Event Description
19 April 2018 New citation required and conclusions have changed In this update we added 16 new studies and excluded 2
studies included in the previous review due to a wrong
comparator.We applied currentMECIR standards aswell
as GRADE to assess the certainty of evidence. The con-
clusions of this review have changed
17 January 2012 Amended Added grant 5R01DK63300-4 info.
C O N T R I B U T I O N S O F A U T H O R S
ECH: study selection, extracting data, performing data analysis, interpretation of data, and drafting the review.
SG: extracting data and assessing risk of bias.
JHJ: conception and study design, searching for trials, study selection, extracting data, assessing risk of bias, performing data analysis,
and interpretation of data.
MI: providing clinical and methodological advice on the review.
MHK: creating search strategies and searching for trials.
RP: providing clinical and methodological advices on the review.
PD: conception and study design, providing clinical and methodological advice on the review, and final approval.
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D E C L A R A T I O N S O F I N T E R E S T
ECH: none known.
SG: none known.
JHJ: none known.
MI: none known.
MHK: none known.
RP: none known.
PD: serves as Co-ordinating Editor of Cochrane Urology. However, he was not involved in the editorial processing or decision-making
for this review. Other editors of Cochrane Urology managed the editorial process, including final sign-off for this review.
S O U R C E S O F S U P P O R T
Internal sources
• Chonnam National University Medical School, Gwangju, Korea, South.
• Minneapolis VA Medical Center, Minneapolis, Minnesota, USA.
• University of Minnesota, Minneapolis, Minnesota, USA.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review was based on a published protocol and was an update of a Cochrane Review first published in 2009 (Garimella 2009).
Major differences between the previous review and the update include the following.
• A more comprehensive search performed using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, LILAC,
and Web of Science), trials registries, other sources of grey literature, and conference proceedings with no restrictions on the language
of publication or publication status.
• Types of interventions: we reclassified the types of intervention according to the drug class.
• Types of outcome measures: we renamed primary and secondary outcomes and added details in ’Method and timing of outcome
measurement’ for all outcomes.
• We applied the GRADE approach and the Cochrane ’Risk of bias’ assessment tool to assess the certainty of evidence.
• We added new type of alpha-blocker (silodosin) as a comparator.
• We did not perform subgroup analyses based on naftopidil dose.
• We included studies using a tamsulosin dose of 0.4 mg as a comparator.
• Although the relevant outcomes could not be used in analyses, we identified one trial comparing naftopidil to placebo.
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N O T E S
We have based parts of the Methods section of this review on a standard template developed by the Cochrane Metabolic and Endocrine
Disorders Group, which has been modified and adapted for use by Cochrane Urology.
Large parts of the background section of this review were based on that of a published review on silodosin for the treatment of lower
urinary tract symptoms in men with benign prostatic hyperplasia (Jung 2017). This was done with explicit approval of both the authors
of this published review and the Cochrane Urology Editorial Group.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenergic alpha-Antagonists [adverse effects; ∗therapeutic use]; Naphthalenes [adverse effects; ∗therapeutic use]; Piperazines [adverse
effects; ∗therapeutic use]; Prostatic Hyperplasia [∗complications]; Prostatism [∗drug therapy; etiology]; Randomized Controlled Trials
as Topic; Sulfonamides [adverse effects; therapeutic use]
MeSH check words
Humans; Male
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